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Abstract 
 
Decisions about the use of psychotropic medication in pregnancy are an ongoing challenge for clinicians 
and women with mental health problems, owing to the uncertainties around risks of the illness itself to 
mother and fetus/infant, effectiveness of medications in pregnancy and risks to the fetus/infant from in 
utero exposure or via breast milk. These consensus guidelines aim to provide pragmatic advice 
regarding these issues. They are divided into sections on risks of untreated illness in pregnancy; general 
principles of using drugs in the perinatal period; benefits and harms associated with individual drugs; 
and recommendations for the management of specific disorders. 
 
Introduction 
The British Association for Psychopharmacology (BAP) has published a series of evidence-based 
guidelines for the use of drugs in patients with psychiatric disorders with the emphasis on producing 
comprehensive, concise and useable guidance based on a review of the relevant evidence (see 
www.bap.org.uk). This new guideline relates to the use of psychotropic medication during the 
perinatal period (see definition of this below). 
Guidelines proliferate in areas of clinical uncertainty. Although there have been many studies 
published in recent years, there remains a paucity of high-quality or consistent evidence to guide 
psychotropic prescribing in the perinatal period. So clinicians are perhaps more dependent on 
guidelines in this area than in others. In the UK, three main bodies produce sets of guidelines exist 
regarding the use of psychotropics: the National Institute for Health and Care Excellence (NICE), the 
Scottish Intercollegiate Guidelines Network (SIGN) and the BAP. Advice relating to prescribing in 
pregnancy is also available from the UK Teratology Information Service (UKTIS). 
The NICE perinatal guidelines repeatedly emphasise the need for access to advice from experts 
regarding the use of psychotropics in the perinatal period (NICE CG192, statement 1.10.3). This is not 
always readily available. The goal of these BAP guidelines is to provide concise and specific guidance 
for health care professionals. 
 
Methodology employed in creating this guidance 
A consensus meeting was held under the auspices of the BAP in 2012 involving experts in the field of 
perinatal psychiatry, psychopharmacology, teratology, infant and child development and service user 
representatives. Current clinical practice, existing UK guidance and key studies relevant to undertaking 
a risk/benefit analysis of psychotropic use in the perinatal period were critically reviewed. Given the 
high levels of anxiety around the use of medication in the perinatal period, the consensus group were 
keen to achieve a guideline to support evidence-based shared decision making between clinician and 
patient. Development of this BAP guideline was paused pending the publication of NICE guidelines in 
2015 (NICE, 2015a) to ensure that patients and clinicians were not faced with inconsistent advice. The 
residual need for complementary guidance that included practical clinical recommendations was, 
however, clear and work on the BAP guidelines was continued. 
These BAP guidelines are based upon a selective review of key relevant studies, reviews and 
guidelines, including those from NICE, SIGN (SIGN, 2012), other guidelines published in 2014 and 2015 
such as those from British Columbia in Canada (BC Reproductive Mental Health Programme and 
Perinatal Services BC, 2014) and from Denmark (Larsen et al., 2015), UKTIS published monographs 
(https://www.toxbase.org/) and consensus among the authors following iterative circulation of the 
guideline manuscript. 
Given the broad scope of the literature on the risks of all classes of psychotropic drugs in the perinatal 
period, the risk/ benefit ratios for pharmacological treatments across all psychiatric disorders (in 
pregnancy and, when this is not available, in non-pregnant women and men) and the impact of these 
disorders themselves on fetal and infant outcomes, it was not possible for the consensus group to 
undertake a comprehensive review of the entire evidence base. Rather there has been a focus on 
summarising data and making recommendations. 
 
Overview of the guidance 
Scope and target 
The term ‘perinatal’ is used inconsistently in different situations. In these guidelines, for brevity, 
‘perinatal’ is used to include the entire period of pregnancy, the preconception period and the 
postnatal period (conventionally consider the first year after birth). 
These guidelines cover the main psychiatric disorders in which psychotropics are prescribed in 
adulthood. The focus is on the factors that guide treatment. Identification and assessment of 
psychiatric illnesses in the perinatal period are not covered. For these issues the reader is referred to 
the NICE Antenatal and Postnatal Mental Health guidelines (NICE, 2015a). The focus is specifically on 
psychopharmacological treatments, but with reference to neuromodulatory treatments, particularly 
electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS). 
The intention of these guidelines is to support and facilitate evidence-based practice. There are rarely 
unequivocally ‘correct’ or ‘incorrect’ decisions in the treatment of psychiatric disorders. Given the 
complexity of the risk/benefit equations when dealing with prescribing in pregnancy, this is even more 
the case. As a result, these guidelines should not be read as a definitive set of instructions as to what 
to do or not do. The consensus group’s strong view was that the generic factors that need to be 
considered in relation to prescribing in the perinatal period form the most important section in the 
guideline given the relatively few situations in which the evidence is such to allow for a categorical 
recommendation. 
To complement NICE (NICE, 2015a), this review focuses on the evidence necessary to address NICE 
guidelines statement 1.4.3: ‘Discuss treatment and prevention options and any particular 
concerns the woman has about the pregnancy or the fetus or baby. Provide information to the woman 
and, if she agrees, her partner, family or carer, about: 
 
• The potential benefits of psychological interventions and psychotropic medication. 
• The possible consequences of no treatment. 
• The possible harms associated with treatment. 
• What might happen if treatment is changed or stopped, particularly if psychotropic medication is 
stopped abruptly.’ 
 
There are limited data regarding the benefits of psychotropics specifically in pregnancy owing to the 
difficulties of conducting randomised controlled trials (RCTs) in this area. As a result, it is usually 
necessary to extrapolate from population data regarding the efficacy of medications in specific 
disorders generally. The reader is directed to relevant BAP and NICE guidelines regarding these. 
Similarly, there are limited data on the risks of stopping medication specifically in the perinatal period. 
Again, there is a need to extrapolate data from the more general use of drugs. Consequently, this 
guidance focuses particularly on the possible consequences of no treatment and the potential harms 
associated with treatment. 
 
How to use the guidance 
The guidance comprises four main parts: ‘Risks of untreated illness in pregnancy’ describes the risks 
to mothers and their children of psychiatric illness particularly when untreated; ‘Using medication in 
the perinatal period’, relates to general principles of using medication in the perinatal period; ‘Benefits 
and harms associated with individual medications’ reviews the risks associated with specific 
psychotropic medications; ‘Recommendations for the pharmacological management of specific 
disorders’ provides guidance on the management of psychiatric disorders in the perinatal period. 
The guideline uses the convention of presenting summary conclusions and recommendations at the 
end of subsections in the form of bullet points in italics. Note that sections on ‘Recommended 
principles of prescribing to women in the perinatal period’, ‘Recommendations regarding discussion 
of the risks and benefits of psychotropics with women’ and ‘Recommendations 
For the pharmacological management of specific disorders’ areentirely composed of 
conclusions/recommendations. All recommendations have been refined iteratively through reviews 
of drafts of this paper. 
Many readers will use this document to obtain guidance about the management of a specific 
condition. However, we would recommend that the reader first reviews the general principles 
described in ‘Using Medication in the perinatal period’. Subsequently, guidance in ‘Recommendations 
for the pharmacological management of specific disorders’ should be supplemented with the relevant 
information described in ‘Risks of untreated illness in pregnancy’ on the possible consequences of no 
treatment and in ‘Benefits and harms associated with individual medications’ regarding the potential 
harms associated with treatment, together with guidance in other disorder specific BAP guidelines. 
Unlike other BAP guidelines, this guidance does not describe the strength of evidence supporting the 
recommendations made. 
This is primarily because the conventional hierarchy of evidence is not applicable to much of the 
perinatal psychopharmacology field given the lack of RCTs. Most recommendations would be classed 
as ‘standards of good practice’ based on the collective view of the consensus group. Additionally, 
throughout the guideline, statements regarding the magnitude of effects have been approximated to 
the nearest ‘round’ number to avoid the impression of precision, which is rarely the case in the 
perinatal literature, and/or due to inconsistencies between studies. A convention has been used 
where percentage increased or decreased risk is used for amounts of <100% and for amounts greater 
than this the change is reported as an x-fold difference. In addition to the change in risk, which can be 
misleading when presented in isolation, absolute risks (e.g. with and without treatment) are presented 
to help interpretation. 
Data informing these guidelines are constantly emerging. Prescribers are advised to seek advice as to 
whether there is information that would modify the recommendations made in these guidelines that 
has become available subsequent to their publication. Information on fetal risk may be obtained from 
UKTIS (http://www.uktis.org/). This guideline will be updated and re-published in due course. If the 
authors identify recommendations that need to be modified in the interim, these will be posted at 
http://www.bap.org.uk/perinatalupdates. 
 
Risks of untreated illness in pregnancy 
The importance of this issue is underscored by a recent UK analysis that has found that one in 25 
women aged 20–35 who commit suicide do so in the perinatal period. Importantly, these women were 
twice as likely to be actively receiving mental health care (Kim and Silver, 2016). 
Many of the data regarding the risks of untreated mental illness during pregnancy relate to mothers 
with anxiety and/or depression, with only limited information on other illnesses. 
 
Risk of relapse during pregnancy and postnatal episodes of illness 
Pregnancy is not protective against mental illness. If a mental illness is untreated because the woman 
makes a decision to discontinue psychotropic medication prior to, or soon after conception, there may 
be an increased risk of relapse. A variety of studies suggest this may depend on the severity of the 
illness as indicated, for example, by the level of services with which she is engaged. Very high rates of 
relapse of depression (70%) have been found in some studies (Cohen et al., 2004, 2006) when women 
have discontinued antidepressant medication. These studies were conducted in psychiatric settings 
and recruited women with histories of recurrent depression. However, in a study recruiting from 
obstetric settings, likely to include women with milder forms of depression, the risk for onset of a 
major depressive episode was similar in women whether or not they continued antidepressant 
medication (Yonkers et al., 2011). 
Mental illness in pregnancy may persist postnatally. Depression in pregnancy is one of the strongest 
predictors of depression postnatally (Robertson et al., 2004). Additionally, antenatal poor mental 
health may increase the risk of different/ additional postnatal mental illness. For example, up to one 
third of women with active bulimia in pregnancy also develop depression postnatally (Franko et al., 
2001; Morgan et al., 2006). 
There are few studies addressing the impact of pregnancy on severe mental illnesses (Jones et al., 
2014). Although some studies have reported lower prevalence of new onset and recurrence of both 
schizophrenia and bipolar disorder in pregnancy (Munk-Olsen et al., 2006, 2009) other studies, at least 
for bipolar disorder, have reported very high prevalence of recurrence (e.g. 85%) in women 
discontinuing prophylactic medication (Viguera et al., 2007b).  
 
Conclusions/Recommendations 
• Pregnancy is not protective against episodes of mental illness. 
• Findings on the risk of relapse of unipolar depression if medication is stopped during or prior to 
pregnancy are inconsistent, possibly depending on severity of illness. 
• Poor mental health in pregnancy is a strong predictor of mental illness postnatally.  
 
Impact of untreated mental illness on antenatal care and the woman’s partner and family 
 
Mental illnesses are associated with a range of behaviours that have a negative impact on pregnancy 
outcome. Depressed women appear more likely to smoke, drink alcohol or use illicit substances in 
pregnancy (Shah and Howard, 2006; Zhu and Valbo, 2002; Zuckerman et al., 1989); the same 
observation applies to pregnant women with bipolar disorder, psychosis and eating disorders (Jones 
et al., 2014; Micali et al., 2016a). 
 
Self-neglect and lack of motivation in depression, and other mental disorders, may also lead to poor 
self-care and diet. Kim and colleagues (2006) found that women with a selfreported past history of 
psychiatric disorder delayed seeking antenatal care and were at higher risk of inadequate antenatal 
care. 
A woman’s partner and family are also likely to be affected if she is mentally unwell. For example, 
maternal depression is known to be a risk factor for paternal depression in the postnatal period 
(Bradley and Slade, 2011; Burke, 2003). Paternal mental illness may in turn affect the interaction 
between the father and the baby, and the implications for the baby and other children of both parents 
being unwell needs to be considered. 
 
Conclusions/Recommendations 
• Women with depression, bipolar disorder, eating disorders or schizophrenia are more likely to misuse 
alcohol, nicotine and other substances during pregnancy which could negatively impact pregnancy 
outcomes. 
• Women with mental illnesses may utilise antenatal care in sub-optimal ways. 
• Maternal depression affects the whole family and increases the risk of paternal mental illness.  
 
Risks related to untreated depression on pregnancy outcome and offspring development 
Although there is evidence for an association between depression in pregnancy and an increased risk 
of adverse pregnancy and neonatal outcomes, including preterm delivery and low infant birthweight 
(Alder et al., 2007; Grote et al., 2010), there are few studies which compare women with untreated 
depression to women taking antidepressant medication. This is the information women need in order 
to weigh the risks and benefits of treatment. Among these studies there are a number of 
methodological issues which make comparison and meta-analysis challenging, including the fact that 
women who continue on antidepressants in pregnancy may represent a more severely unwell group 
but also may have lower depression scores and better functioning while on antidepressants. 
Additionally, there is the issue of shared genetic risk, which may be particularly pertinent when 
considering offspring development. 
 
Fetal growth and birthweight.  
The majority of studies comparing the offspring of mothers with untreated depression with those of 
non-depressed mothers report an association between maternal depression and restricted fetal 
growth and lower birthweight (Davalos et al., 2012; Diego et al., 2009; Field et al., 2006, 2008; Steer 
et al., 1992). Diego et al. (2009) found that 20% of infants born to mothers with antenatal depression 
had low birthweight compared to 5% in the non-depressed group. Steer et al. (1992) found that risk 
of low birthweight rose 5–7% for each additional Beck Depressive Inventory point when the mother 
rated the severity of her depression. 
 
In studies that compare neonates of unmedicated depressed mothers to mothers treated with 
antidepressants the results are less conclusive (Davalos et al., 2012). Using population-based linked 
health data, it has been reported that neonates exposed to selective serotonin reuptake inhibitors or 
(SSRIs) (n = 1451) and neonates exposed to untreated depression (n = 14,234) both had lower 
birthweights than control neonates (n = 92,192) (Oberlander et al., 2006). When outcomes were 
compared between SSRI exposed and non-exposed neonates (matched in terms of severity of 
depressive illness the mother suffered from), SSRI exposure in pregnancy was associated with an 
increased incidence of birthweight below the 10th percentile. The authors suggested that SSRI 
exposure and depressed maternal mood had an additive negative effect (Oberlander et al., 2006). In 
contrast, two other studies, albeit with much smaller samples of women, have found no difference in 
birthweight between infants of mothers with untreated depression in pregnancy, those whose 
mothers were treated with SSRIs in pregnancy and a control group whose mothers were not depressed 
(Suri et al., 2004; Wisner et al., 2009). 
 
Preterm delivery. In studies comparing infants born to unmedicated depressed mothers with those of 
a non-depressed control group, the majority of studies report shorter length of gestation (Davalos et 
al., 2012). Preterm delivery (defined here and elsewhere in the guideline as delivery before 37 weeks’ 
gestation) is around three times as likely for depressed versus non-depressed mothers with absolute 
rates being approximately 25% for depressed and 7–10% for non-depressed mothers (Diego et al., 
2009; Field et al., 2006; Steer et al., 1992). The risk of preterm delivery appears to be influenced by 
the severity of depression (Li et al., 2009). A meta-analysis identified five studies of antenatal 
depression and risk of preterm birth for which stratification by antidepressant medication was 
possible and found comparable gestational ages for depressed women treated and not treated with 
antidepressants (Grote et al., 2010). 
 
Other pregnancy and neonatal outcomes. Data linking untreated depression with risks of other 
outcomes are sparse and results inconsistent. Untreated depression in pregnancy has been associated 
with increased rates of Caesarean section in some studies (Chung et al., 2001; Oberlander et al., 2006), 
but not others (Wisner et al., 2009). Higher rates of neonatal intensive care 
unit admissions were found in some studies (Chung et al., 2001), but again not in others (Suri et al., 
2004; Wisner et al., 2009). 
 
Risks of untreated antenatal illness on the infant’s development and future psychopathology. Much of 
the data on this issue come from women with depressive symptoms and anxiety not necessarily 
meeting criteria for a major depressive episode or an anxiety disorder. Additionally, the shared 
genetics between the mother and the child is a confounder that is usually not addressed in the 
research described below. 
Maternal antenatal depression and anxiety symptoms are reported to be associated with an increased 
risk of neurodevelopmental and psychopathological consequences for the offspring spanning into 
childhood and adolescence (Talge et al., 2007). This is thought to be, at least in part, attributable to 
fetal programming: the effect of the uterine environment, during specific critical periods for different 
behavioural outcomes, on fetal development with long-term effects on the child (Sandman et al., 
2011). Several studies have shown that these altered outcomes are independent of many possible 
confounding factors, including smoking, alcohol consumption and anxiety and depression postnatally, 
suggesting possible causal associations with maternal illness during pregnancy (O’Donnell et al., 2014). 
Most children are not affected, and those that are can be affected in different ways, probably owing 
to different genetic vulnerabilities and the quality of postnatal care. The neurodevelopmental 
outcomes for which there is evidence of an increased risk among offspring of women with anxiety or 
depressive symptoms during pregnancy include emotional problems, symptoms of attention deficit 
hyperactivity disorder (ADHD) and conduct disorder, impaired cognitive function and schizophrenia 
(Glover, 2014). There are some reports of an increased risk of autism, but the evidence is less 
consistent (Glover, 2014). 
In the large ALSPAC population study, it was found that if the mother was in the ‘top’ 15% for 
symptoms of anxiety or depression in pregnancy, her child was at double the population risk (of 5–
10%) for emotional and behavioural problems at ages 4 and 7, including symptoms of ADHD and 
conduct disorder (O’Connor et al., 2003). Similar results are seen when the child is 13 years old 
(O’Donnell et al., 2014).  
In the only longitudinal study so far that has followed-up offspring of mothers who were diagnosed 
with depression during pregnancy up to adolescence, antenatal depression was associated with an 
increased risk of both depression and antisocial behaviour in the offspring (Pawlby et al., 2009, 2011), 
an effect that was specific to antenatal depression and was not present in the offspring of mothers 
who were only depressed postnatally (Hay et al., 2008). The risk of developing depression in the 
adolescent offspring of a mother who had suffered from antenatal depression was approximately 
three-fold that of control offspring (approximate absolute risk of 52% vs 24%) though the sample size 
was small and hence the 95% confidence interval for the increased risk was wide (Pawlby et al., 2009, 
2011). Data collected in the same offspring at age 25 were consistent with these earlier findings (Plant 
et al., 2015a). Evidence from the same study also shows that antenatal depression increases the risk 
of the offspring being exposed to maltreatment in childhood, by approximately four-fold 
(Pawlby et al., 2011), especially if the mother was herself exposed to maltreatment in childhood (Plant 
et al., 2013). This increased risk was not attributed to the depressed mothers themselves being more 
likely to be perpetrators of the maltreatment, but rather was due to an increased risk of maltreatment 
from other adults in the immediate environment. 
The effect of the emotional state of the mother during pregnancy on fetal neurodevelopment is not 
confined to those with a diagnosed mental illness and other forms of stress also appear to have an 
effect. For example, in a study correlating antenatal life events with child cognitive development at 17 
months, Bergman et al. found that antenatal stress accounted for 17% of the variance in cognitive 
ability after allowing for a range of confounders, including postnatal maternal mood (Bergman et al., 
2007). 
 
Impact of depression postnatally. Maternal depression has been associated with various patterns of 
interactions with their babies that are, in turn, associated with disordered learning and development. 
These overlapping maternal behaviours can be characterised in three groups: withdrawn interactions, 
where the parent does not actively engage with the baby; hostile and intrusive interactions; and 
general sadness and insensitivity (Sutton et al., 2012). A lack of active, responsive, engagement with 
the infant is associated with poor infant learning and poorer cognitive development. These early 
effects tend to persist throughout childhood. Boys of mothers who were depressed do not achieve 
as well at age 16 in public exams as others (Murray et al., 2010). 
Conclusions/Recommendations 
• There is limited evidence regarding the risks of untreated, as opposed to treated, depression on the 
pregnancy and infant outcomes. 
• Untreated depression may be associated with low birthweight. The magnitude of this risk appears to 
correlate with severity of illness. It is, however, unclear if this risk is altered by treatment with 
antidepressants. 
• Untreated depression may be associated with an increased risk of preterm delivery. Again, the risk 
appears to correlate with severity of depression. Antidepressant treatment does not seem to influence 
the risk once women are matched on severity of depression. 
• No firm conclusions can be drawn about potential associations of untreated depression with any 
other adverse pregnancy outcome. 
• Antenatal maternal depression and anxiety has been associated with a range of adverse outcomes 
for the child. These include emotional problems, symptoms of ADHD, conduct disorder, impaired 
cognitive function, schizophrenia and possibly autism. 
• Antenatal, but not postnatal, depression is associated with an increased risk of depression and 
antisocial behaviour in offspring. It is unknown if treatment of antenatal maternal ill health decreases 
these risks. 
• Depression postnatally can lead to poor engagement with infants, which in turn can lead to poor 
infant learning and cognitive development, with these effects persisting throughout childhood. 
• There is a lack of evidence that treating depression postnatally can reduce these risks. 
• The adverse effects of maternal antenatal and postnatal ill health appear to be additive. 
 
Risks related to anxiety, stress and insomnia 
There is a great deal of overlap between depression and anxiety and much of the information in ‘Risks 
related to untreated depression on pregnancy outcome and offspring development’ 
(especially ‘Risks of untreated antenatal illness on the infant’s development and future 
psychopathology’) potentially relates to both. 
Anxiety disorders are common in the perinatal period, but often over-looked. The experience of 
childbirth can be so emotionally intense as to precipitate the development of post-traumatic- like 
symptoms in approximately one-quarter of women after vaginal deliveries (Olde et al., 2006). Some 
observational studies suggest a higher incidence of obsessive-compulsive disorder (OCD) in the 
postpartum period, although data from prospective studies are limited, and possibly not generally 
applicable (McGuinness et al., 2011; Speisman et al., 2011). 
Postnatal anxiety in mothers is possibly associated with childhood somatic (such as recurrent 
abdominal pain) and psychological (such as emotional and conduct difficulties) difficulties (Glasheen 
et al., 2010). 
A systematic review suggests self-reported poor sleep during pregnancy (and in the postpartum year) 
is associated with an increased risk of postpartum depression: the association being less marked in 
studies in which sleep was assessed objectively (Lawson et al., 2015). 
A systematic review and meta-analysis which found no evidence for the potential benefit of 
‘preventive’ antenatal interventions (including educational classes and group antenatal care) in non-
distressed women, did find evidence for the potential benefit of treatment interventions (including 
relaxation and mindfulness) in women who were already distressed (Fontein-Kuipers et al., 2014). 
There is also evidence that psychological interventions designed to enhance coping and self-regulation 
in women following preterm birth reduces maternal depressive and anxiety symptoms and parenting 
stress (Kraljevic and Warnock, 2013). However, routine screening for the presence of anxiety is 
challenging, with no scale having sufficiently robust psychometric properties for routine clinical use 
(Brunton et al., 2015); similar problems are seen when assessing ‘psychosocial stress’ during 
pregnancy (Nast et al., 2013). 
Conclusions/Recommendations 
• Anxiety and stress in mothers during pregnancy can be associated with long-term behavioural and 
mental health problems in offspring. 
• There is less evidence regarding insomnia but it may be associated with an increased risk of 
postpartum depression. 
• It is unclear whether antenatal interventions to treat anxiety and insomnia impact on infant 
outcomes. 
• Anxiety disorders can be problematic postnatally. There is doubt as to whether the incidence of OCD 
is increased or not. PTSD however can present, especially after traumatic 
deliveries. 
 
Risks related to bipolar disorder 
Pregnancy does not protect from recurrences of bipolar disorder. In a prospective cohort study of 
pregnant women with bipolar disorder who were well, taking prophylactic mood stabilisers, those 
who discontinued the medication proximate to conception had a two-fold higher recurrence risk (86% 
vs 37%), a four-fold shorter time to first recurrence (9 vs >40 weeks) and a four- to five-fold increased 
time spent ill in pregnancy than those who remained on the medication (40% vs 9% of the pregnancy) 
(Viguera et al., 2007b). 
 
Immediately after childbirth the risk of postpartum psychosis (including mania, mixed affective states 
and psychotic depression) and episodes of bipolar disorder increases in women with bipolar disorder, 
but there is some debate as to what extent. A recent meta-analysis of studies reporting on postpartum 
recurrences found that the rates varied widely; for bipolar disorder between 9% and 75%; and for 
puerperal psychosis between 14% and 57% (Wesseloo et al., 2016). This may well reflect differences 
in definitions of recurrence, the range of phenotypes being included and, importantly, whether 
women were or were not on medication. Women with bipolar disorder who were medication free 
during pregnancy had a significantly higher risk of postpartum relapse (approximately 65% vs 25%) 
than those who were taking prophylactic medication (Wesseloo et al., 2016). 
A population-based cohort study in Sweden provides the only evidence on outcomes for infants of 
mothers with untreated bipolar disorder in pregnancy. The data are confounded because mothers 
with bipolar disorder were more often smokers, overweight and alcohol or substance abusers, 
regardless of treatment, when compared to unaffected mothers (Boden et al., 2012a). Both untreated 
and treated women with bipolar disorder had increased risks of Caesarean delivery, instrumental 
delivery and a non-spontaneous start to delivery, as well as preterm delivery (8% vs 5%) compared to 
controls. There was no significant difference between groups for very preterm births (<32 weeks’ 
gestation). The risks of microcephaly and neonatal hypoglycaemia were increased in the infants of 
untreated women with bipolar disorder when compared with the other two groups. 
Conclusions/Recommendations 
• Risks of relapse in the immediate postpartum period for women with a history of bipolar disorder or 
postpartum psychosis are particularly high. 
• The risk of recurrence appears to be higher if women with bipolar disorder are not taking medication 
prior to or during pregnancy. 
• Bipolar disorder, whether treated or untreated, appears to be related to an increase in preterm 
delivery, Caesarean section and instrumental delivery. However, the strength of these data is poor. 
 
Risks related to schizophrenia and other psychotic illnesses 
Overall, pregnancy is not protective against acute or chronic psychosis and there is an increased risk 
of acute psychotic relapse in the postnatal period, although the increased risk is not as high as seen 
for bipolar disorder (Munk-Olsen et al., 2009). The risk of a postnatal psychotic episode in the context 
of chronic schizophrenia is evenly elevated throughout the first postnatal year (unlike bipolar disorder, 
where risk rises rapidly in the early days and remains raised for the first few months) (Munk-Olsen et 
al., 2009). 
Compared to the general population, women with schizophrenia are more likely to have adverse 
obstetric and neonatal outcomes (Bennedsen et al., 1999, 2001; Cannon et al., 2002; Dalman et al., 
1999; Howard et al., 2003; Jablensky et al., 2005; Vigod et al., 2014). Potential mechanisms for this 
include the effects of the underlying schizophrenic illness; lifestyle factors (e.g. smoking, alcohol and 
drug misuse and poor nutrition), medical morbidity (in particular diabetes mellitus, obesity and 
hypertension); social adversities (e.g. poverty, domestic violence); and poor antenatal 
care (Abel and Howard, 2014; Jones et al., 2014). It is hard 
to untangle an additional contribution to adverse outcomes from 
psychotropic medication (including antipsychotics and other 
commonly co-prescribed medications such as antidepressants, 
mood stabilisers and benzodiazepines) given a relative paucity of 
data from mothers who were ill and untreated. A study of a nationwide population-based dataset in 
Taiwan found no significant difference in low birthweights or preterm delivery for infants of women 
with treated or untreated schizophrenia (Lin et al., 2010). However, psychotic illnesses are associated 
with an increased rate of stillbirths and neonatal deaths (Howard, 2005; King-Hele et al., 2009; Webb 
et al., 2010). 
Conclusions/Recommendations 
• Pregnancy is not protective against episodes of psychosis in women with schizophrenia. 
• Schizophrenia is associated with a range of adverse obstetric and neonatal outcomes. The causes of 
this and the impact of medication is hard to ascertain.  
 
Risks related to ADHD 
The challenges of motherhood are likely to be particularly difficult for a woman with ADHD suffering 
from poor concentration and impulsivity. Untreated or inadequately treated ADHD can result in risk-
taking, which may potentially place the mother and child at risk, both prenatally and postnatally. There 
is also an association between ADHD and substance misuse, which may raise additional risks for the 
fetus and infant (see ‘Risks related to substance misuse’). It is important to note that there is some 
evidence that adequate treatment of ADHD might decrease substance misuse (Wilens, 2003). 
Impulsivity can be a major element of ADHD for some patients. This may increase the risk of unplanned 
pregnancy (Besag, 2014). This is supported by the observation of higher rates of induced abortions in 
women with ADHD (Haervig et al., 2014). However, this may be confounded by the observation in the 
same study of women on ADHD medication being younger, more likely to be single, having lower 
education, being more likely to be receiving benefits, and to be using other psychotropics than other 
pregnant women. 
 
Risks related to eating disorders 
Eating disorders (ED) affect approximately 5–10% of women of childbearing age (Smink et al., 2012). 
ED onset is in adolescence and young adulthood (Micali et al., 2013) and usually the disorders have a 
chronic course.  
ED can result in menstrual dysfunction and ovulation problems, difficulties conceiving and an 
increased need for fertility treatment (Easter et al., 2011; Freizinger et al., 2010; Micali et al., 2014). 
However, ED are common in the perinatal period, with recent studies estimating the prevalence of 
active ED in pregnancy between 5% and 7.5% (Bulik et al., 2007; Easter et al., 2013; Micali et al., 
2016b). There is some evidence that ED symptoms can improve during pregnancy (Bulik et al., 2007; 
Easter et al., 2015), however, they do not completely disappear and relapse, recurrence and new onset 
ED occur in the postpartum period (Blais et al., 2000; Crow et al., 2008). 
Women with active and past history of ED are at high risk of developing perinatal depression and 
anxiety (Easter et al., 2015; Micali et al., 2011b). A meta-analysis showed that ED, particularly anorexia 
nervosa (AN), is also associated with adverse birth outcomes including low birthweight (around 0.2 kg 
less than babies born to non-affected mothers) (Solmi et al., 2014) and babies born small for 
gestational age (16% of babies born to mothers with AN below the 10th centile of sex and gestational 
specific birthweights) (Micali et al., 2016b). However, opposite findings have been reported for 
women with bulimia nervosa (BN) and binge eating disorder (BED) having babies large for gestational 
age (Linna et al., 2014). 
Conclusions/Recommendations 
• ED can reduce fertility but are still common in the perinatal period. 
• ED symptoms may improve during pregnancy. 
• Women with ED are at increased risk of developing depression and anxiety during pregnancy and 
postnatally perinatally. 
• AN is associated with low infant birthweights. 
• BN and BED are associated with infants born large for gestational age. 
 
Risks related to substance misuse 
Substance misuse/dependence are important factors in the morbidity and mortality of pregnant 
women, including suicides. Women who engage with addiction services have better outcomes with 
better antenatal health care than those women who do not engage. The World Health Organisation 
(WHO) has published evidence-based guidelines on the identification and management of substance 
use in pregnancy with specific recommendations (WHO, 2014). Substance use is also a significant 
factor in the deaths of women in the first year after pregnancy (Knight et al., 2015). 
 
Smoking/nicotine dependence. Smoking is the leading preventable cause of fetal morbidity and 
mortality in the UK. Women with mental disorders are more likely to be smoking at conception, at 
antenatal booking, and up until delivery (Goodwin et al., 2007) and to find it more difficult to stop 
smoking, even if they accept referral to smoking cessation services (Howard et al., 2013). Smoking is 
associated with an increased risk of miscarriage, congenital malformations, low birthweight, 
prematurity, stillbirths, sudden infant death syndrome (SIDS) and physical and mental disorders in 
childhood (Royal College of Physicians, 2010). There is good evidence from a large Cochrane 
systematic review of 77 RCTs including >29,000 individuals that smoking cessation programmes 
reduce the proportion of pregnant women continuing to smoke, and improve rates of low birthweight 
and prematurity (Chamberlain et al., 2013). 
The complexity of the relationship between factors influencing the infant’s outcome is further 
illustrated by research investigating the association between maternal smoking during pregnancy and 
the risk of ADHD in offspring (Langley et al., 2012). This study demonstrated that the risk to the 
offspring is similar whether it is the mother or father who smoked during pregnancy and this was not 
as a result of passive smoking on the part of the mother (Langley et al., 2012). This suggests that 
genetic rather than intrauterine effects may be causal. 
Alcohol misuse/dependence. Alcohol consumption in pregnancy is associated with miscarriage, 
preterm birth, low birthweight and developmental delays encompassed within the umbrella term of 
Fetal Alcohol Spectrum Disorders (Makarechian et al., 1998; O’Leary et al., 2009). Alcohol use in 
pregnancy is predicted by pre-pregnancy alcohol consumption (i.e. quantity and frequency of typical 
drinking) and exposure to abuse or violence (Skagerstrom et al., 2011), though there is some 
inconsistency in the association between antenatal psychiatric disorders or symptoms and alcohol 
misuse (Lancaster et al., 2010; Skagerstrom et al., 2011). 
Although alcohol use is key to development of fetal alcohol syndrome, other factors such as other 
drug use e.g. nicotine and cocaine, stress and malnutrition increase the impact of alcohol use on the 
fetus and should be considered (Abel and Hannigan, 1995). 
 
Cannabinoids. Cannabis is the most commonly used illicit drug, with perinatal prevalence rates up to 
about 40%, although the majority stop once they know they are pregnant (Forray and Foster, 2015). 
Cannabis has been associated with adverse outcomes such as low birthweight and preterm labour 
(Metz and Stickrath, 2015). Cannabis use often occurs with other drugs such as tobacco and alcohol 
which also have an independent effect on fetal outcomes (e.g. Kuhn et al., 2000). 
 
Opioid misuse/dependence. Opioid dependence is associated with increased maternal and neonatal 
complications. Untreated opioid dependence is associated with increased risk of fetal growth 
retardation, placental abruption, fetal death and preterm delivery (Center for Substance Abuse 
Treatment, 2008). 
 
 Stimulant misuse/dependence. The misuse of amphetamines, cocaine and stimulant-type novel 
psychoactive substances (NPS) is a public health problem presenting with medical, psychiatric, legal 
and socio-economic consequences. Cocaine and other stimulant use during pregnancy has been 
associated with preterm labour, congenital anomalies, intrauterine growth retardation (IUGR), 
placental abruption, low-birthweight infants, neonatal death and SIDS (Debooy et al., 1993; Fox, 1994; 
Ryan et al., 1987). Maternal complications include a pre-eclampsia-like syndrome, acute pulmonary 
oedema, seizures, cardiac arrhythmia and sudden death (Fox, 1994; Ryan et al., 1987). Prenatal 
cocaine exposure has also been associated with developmental problems among pre-school and 
school-age children, although there are often multiple confounding environmental variables at play 
(Ackerman et al., 2010; Frank et al., 2001). 
Stimulant use prior to delivery is associated with a neonatal withdrawal syndrome including symptoms 
of agitation, vomiting and tachypnoea (Chomchai et al., 2004; Smith et al., 2003). 
 
Benzodiazepine misuse/dependence. These drugs may be a significant problem in pregnant women, 
often taken with opioids. In one study of pregnant opioid dependent women, 44% of women screened 
were positive for benzodiazepine misuse (Jones et al., 2010). See ‘Anxiolytics/Hypnotics’. 
Conclusions/Recommendations 
• Smoking in pregnancy is associated with a range of adverse pregnancy and infant outcomes and it is 
recommended that health professionals refer to pregnancy smoking cessation services and support 
women with engagement with smoking cessation and quit attempts. 
• Alcohol is associated with serious adverse effects including fetal alcohol syndrome. 
• Illicit drug use is associated with a range of adverse fetal and maternal outcomes. 
 
Using medication in the perinatal period 
The management of mental illness in the perinatal period is an area so devoid of evidence in many 
areas, and with risks which are hard to quantify, that the most important element of this document 
are the general principles. One of the most important of these is collaboration between the prescriber 
and the woman, and potentially her partner. 
 
Weaknesses in the data on which perinatal guidelines are based 
Historically, much of the data regarding the risks of psychotropics in the perinatal period have been 
retrospective, with all of the associated biases that this entails. Malformations following exposure are 
more likely to be reported than healthy outcomes owing to increased vigilance in women taking 
medication. This also applies to population datasets. Increased screening for malformations among 
infants exposed in utero to a drug can lead to increased detection, including of minor malformations 
that are of no clinical significance. The literature does not always differentiate between minor clinically 
insignificant malformations and more serious ones, or reports them together. Some data come from 
studies of the use of drugs for non-psychiatric indications, and therefore in populations with 
potentially different vulnerabilities (e.g. the use of anticonvulsants in epilepsy). However, in recent 
years, at least for antidepressants, there have been several cohort studies, particularly from 
Scandinavia, that have reported on large number of exposures in pregnancy (in excess of 100,000). 
Even with this amount of data, it can be difficult to draw conclusions about the reproductive safety of 
these medications. 
There are two major issues that need to be considered when reviewing the literature. Firstly there are 
residual confounding issues such as coexisting alcohol use and smoking, as well as the severity and 
type of psychiatric illness that the mother herself is suffering from. Secondly there is an issue relating 
to multiple statistical tests that are undertaken in some studies exploring the effects of medication on 
a range of factors. For example, a Swedish study of the effects of in utero exposure to antidepressants 
tested multiple comparisons by including many outcomes, 21 different drugs and the impact of 
exposure at multiple time points in pregnancy (Reis and Kallen, 2010). 
The evidence we have on efficacy for most medications specifically in the perinatal period are also 
poor. Most RCTs of psychotropics exclude women who are pregnant or breastfeeding. In general, 
guidelines (e.g. (NICE, 2015a; SIGN, 2012)) have extrapolated efficacy findings from non-pregnant and 
nonbreastfeeding individuals. This seems reasonable as there is little evidence to suggest that the 
efficacy of psychotropics could be different in the perinatal period.  
 
Conclusions/Recommendations 
• Data regarding the risks and benefits of psychotropic medication in the perinatal period have many 
weaknesses, in particular the multiple confounding factors. This makes definitive statements about 
risks and benefits impossible in most cases. 
• There are relatively limited data regarding the efficacy of psychotropics specifically in pregnancy and 
breastfeeding women. It is therefore usually necessary to generalise evidence of efficacy from studies 
in non-perinatal populations. 
 
Recommended principles of prescribing to women in the perinatal period General management issues 
across all childbearing stages 
• Factors influencing management choices in the perinatal 
period include: 
|| Accuracy of the diagnosis. 
|| Illness course, severity, burden and risk when unwell. 
|| Presence of psychiatric and physical comorbidities. 
|| Frequency of, and triggers for, relapse. 
|| Previous perinatal episodes of illness in the women and family history of severe perinatal episodes. 
|| The woman’s treatment history including her responses and tolerability to medication, talking 
therapy and other interventions and her experience of them. 
|| Past episodes of self-harm, suicide attempts and risks to others. 
|| Duration of remissions on and off medication. 
|| Social functioning. 
|| Time to relapse after previous discontinuation. 
|| Time to recovery on reintroduction of medication. 
• Check whether the woman and her family have been sufficiently educated about her illness and 
explain how childbearing may affect its course. 
• Consider the attitudes of the woman and her partner to the balance of risk of recurrence of illness 
and reproductive safety of medication. 
• After a careful consideration of the above factors, it may be that a joint decision is to utilise non-drug 
interventions as alternatives to medication where appropriate. 
• For women on several medications, take a careful history of the indications for each prescribed 
medication and its effectiveness, and minimise the number and dose of medications as far as possible. 
• Using a drug of known efficacy in a particular woman may be preferable to using one of unknown 
efficacy but possible lower pregnancy risk. 
• Sub-therapeutic doses of medication should be avoided. 
• Explore possible substance use/misuse and address this where possible. 
• Because of the high risk of a significant recurrence in the perinatal period and the complexities of 
good care, women with a history of severe mental illness should be under the care of mental health 
services, ideally a specialist perinatal mental health team wherever possible. 
• All women with significant histories of severe mental illnesses should have an individualised perinatal 
mental health care plan drawn up in collaboration with the woman herself and mental health, primary 
care, health visitors, maternity services, neonatology and Children’s Social Care if involved. The care 
plan should be distributed widely among all involved health professionals. 
Such care plans should take into account and describe: 
|| The woman’s obstetric, physical and mental health care needs. 
|| Ongoing medication and psychosocial interventions and steps to address relapse prevention. 
|| Information about any relevant monitoring issues (e.g. of lithium levels), medication dose 
adjustments, interactions with other drugs that could be prescribed in the pregnancy, any relevant 
issues related to delivery and possible risks to the neonate. 
|| Detailed, individualised letters recording discussions and decisions should be written to women and 
copied to all professionals involved. 
|| The specified roles for each professional in terms of monitoring, providing interventions and co-
ordinating care. 
|| Whether or not the woman plans to breast feed and any medication plans for this period of time. 
|| Whether there are any relevant safe guarding issues. The preconception period 
• There should be discussions with all women of childbearing potential who are being prescribed 
psychotropics or with a history of mental illness regarding their risks and benefits related to conception 
and during the perinatal period, as well as options for contraception. For women with a history of 
mental illness considering starting or extending their family more formal extended preconception 
counselling is required, reviewing the women’s current health and the available evidence of fetal risk 
for any drugs she is taking. 
• Pre-conception advice is particularly important where medication is associated with early 
teratogenicity. 
|| There is a particular concern around the use of anticonvulsant mood stabilisers, such as valproate 
or carbamazepine, whose adverse effects may have occurred before confirmation of pregnancy. 
|| Valproate is the only psychotropic contraindicated in women of childbearing potential when used 
for psychiatric indications, although even here there can be very rare exceptions. 
• Options available to women include staying on current regimes, switching to a regime that may be 
associated with fewer adverse fetal and/or maternal effects, or discontinuing treatment entirely. 
• If a decision is taken to discontinue medication, this may need to be done slowly, for example, to 
avoid withdrawal symptoms or to enable monitoring for signs of maternal deterioration. The interval 
following discontinuation during which effective contraception needs to be continued will depend on 
the half-life and teratogenic risk associated with the drug. 
 
During pregnancy 
• Manage pregnancy among women with severe mental illness as a high-risk pregnancy requiring 
more intensive monitoring, with close liaison among professionals (general adult and specialist 
perinatal mental health professionals, obstetricians, midwives, GPs and social services where 
appropriate). 
• Address any modifiable risk factors at baseline and throughout the perinatal period: smoking 
(smoking cessation programmes), obesity (behavioural interventions and consider prescribing 
options), nutritional status (folate supplementation), diabetes mellitus (screen and treat), alcohol and 
drug misuse (refer to specialist services if needed) and domestic violence (refer to advocacy/ voluntary 
sector specialist services). 
• Risk/benefit decisions about staying on medication or discontinuing should be considered as soon as 
possible on discovering a pregnancy and individualised. 
• Generally avoid stopping medication suddenly on discovery of pregnancy since this does not 
necessarily remove risks of malformations and sudden discontinuation of medication may pose risks 
to the mother’s health. 
|| There is a different risk/benefit analysis to be made when continuing/changing pre-existing 
medication, compared with commencing a new treatment. 
• The most important information regarding the likely efficacy of a medication for a particular woman 
comes from the patient’s own past treatment history. If there is strong evidence of a good past 
response to a particular medication, there should be a good reason not to recommend it as the 
medication of choice or to prescribe a medication of unknown efficacy even if with a potentially lower 
risk in pregnancy. 
• In general, avoid switching medication in pregnancy unless the benefits are likely to outweigh the 
risks. 
• Women taking psychotropics during pregnancy that are known to be associated with a significant 
risk of malformations should be offered detailed ultrasound scanning for fetal abnormalities as early 
in gestation as such scanning is possible, if they choose. 
• Monitor for excessive weight gain, and ensure this is managed in line with appropriate guidance (e.g. 
(NICE, 2010c)). Also monitor for gestational diabetes, particularly for women on a second generation 
antipsychotic (SGA), (request an oral glucose tolerance test) and ensure this is managed in line with 
appropriate guidance (e.g. (NICE, 2015b)). 
• Consider high dose folic acid (5 mg/d) where folatelowering drugs are used, although the evidence 
for its benefit has not been shown (Wlodarczyk et al., 2012) and there is a possibility that folate may 
decrease the efficacy of other drugs such as lamotrigine in bipolar disorder (Geddes et al., 2016). 
• Although there may be some potential advantages of changing medications early in pregnancy, by 
mid–trimester there might be fewer, if any, advantages in changing (with the exception of valproate). 
• In later pregnancy, there is also a risk/benefit decision to be considered around risk of neonatal 
adaption syndromes and, for example, persistent pulmonary hypertension of the newborn (PPHN – see 
section ‘Teratogenicity’). 
|| Close to delivery, there needs to be consideration of whether there is any evidence that reduction/ 
discontinuation of medication will alter the risk of neonatal syndromes particular to the medication in 
question, taking into account the risks to the mother of doing so. 
|| For most women, the delivery date is not certain so the woman may be exposed to an ineffective 
dose for several weeks at a time when risks (e.g. of bipolar relapse) may begin to increase. 
|| There is no evidence on how long reduction/discontinuation would need to be for to reduce this risk, 
but 14 days may not be enough (Warburton et al., 2010). 
|| Plans to breastfeed should also be taken into account as this may mitigate discontinuation. 
|| As neonatal adaption syndromes are generally mild and transient, this issue is probably most 
relevant in pregnancies with known fetal problems such as IUGR or malformations. 
• During an admission to the maternity unit, consider the need for a specialist mental health nurse or 
an advocate where appropriate. 
 
The intrapartum period 
• In women with a severe mental illness, it is recommended that delivery should be in hospital. 
• Anticipate potential issues which might arise. 
• Midwives need to be aware of any medication issues, for example the need to stop lithium when the 
woman goes into labour, or any medication that might need to be started immediately following 
delivery, for example in a woman at risk of a postnatal episode. 
• Information needs to be provided as to when and how clinical staff on the maternity ward should 
seek psychiatric advice. 
• Information about potential risks of medication taken during pregnancy on the baby needs to be 
discussed with the relevant neonatologists. Postnatally and during breastfeeding 
• The WHO recommends that ‘infants should be exclusively breastfed for the first 6 months of life to 
achieve optimal growth, development and health’ (World Health Organisation, 2003). 
• Take care with any sedating medication especially in the postnatal period since excessive sedation 
can hinder baby care and breastfeeding. Although sedation can often resolve over a short period after 
starting a medication, alternative options may need to be considered. 
• Advise women against co-sleeping with their babies. 
• Where relevant, consider a discussion about the woman’s parenting capacity and the potential need 
for referral to Children and Families social services. Where a woman has significantly impaired social 
function and poor social support, consider discussing the risk of custody loss. 
• Breastfeeding women with mental illness should have rapid access to psychological therapies, but 
where illness  is more severe, drug therapy may be an essential component of effective treatment. 
Choose treatments for women who are breastfeeding with the lowest known risk and keep in mind 
that there is very limited knowledge about long-term neurodevelopmental outcomes. 
• A guide to the possible risk of breastfeeding while taking a particular drug is the relative infant dose 
(RID) – the daily amount of drug ingested by the infant during exclusive breastfeeding per kg 
bodyweight divided by the maternal daily dose per kg body weight. Information regarding this can be 
found in the Drugs and Lactation Database, 2016 
(https://www.nlm.nih.gov/pubs/factsheets/lactmedfs.html). 
• As in pregnancy, previous treatment response should guide future treatment choices. 
• Where there is no clear evidence base that one drug is safer during breastfeeding than another, the 
best option may be not to switch. 
• There is little clear evidence to support the discarding of breastmilk or timing of breastfeeding in 
relation to time of maternal drug administration. Such recommendations could potentially add to the 
difficulties and challenges of establishing breastfeeding. 
• Monitor the infant for adverse effects such as (but not limited to) over sedation and poor feeding. 
• These recommendations in general apply to term, healthy infants. Great caution should be exercised 
in decisions around maternal psychotropic prescribing for breastfed premature or sick infants, and 
where the mother is taking more than one drug. Recommendations regarding discussion of the risks 
and benefits of psychotropics with women 
• Some degree of discussion is required for all women of childbearing potential being prescribed a 
psychotropic. 
• For women who are considering starting or extending their families the need for more extensive 
preconception counselling should be considered, ideally to be delivered by specialist perinatal mental 
health services for women with the highest or most severe risks (history of bipolar disorder or severe 
mental illness). 
• The main goal of discussions is to individualise the advice to the woman taking into consideration 
her particular history of illness, response to treatment, and attitudes to risk both to her and to the 
baby. 
• See ‘Scope and target’ for a framework described by NICE of the various risks and benefits that need 
to be considered in the discussions. 
• As discussed in ‘Risks of untreated illness in pregnancy’, women should also be aware not only of the 
known or potential risks of medication but also of the evidence that untreated illness in pregnancy may 
be associated with increased adverse effects for the woman herself, her pregnancy, and for infant 
outcomes. 
• Consideration should be given to providing information in a number of ways, for example in both 
verbal and written forms. 
|| There are a number of online resources (e.g. www. medicinesinpregnancy.org from UKTIS) that 
provide evidence-based and updated information to assist women in making informed decisions about 
treatment, although these do not remove the need for detailed individualised assessment and 
discussion of options with a clinician. 
• The nature and level of discussion regarding the risks and benefits of psychotropics in the perinatal 
period should be tailored to the needs of the woman and, where relevant and agreed by the woman, 
her partner. 
• Women may be concerned about the risk that any children they have may suffer from mental illness. 
It is therefore important to discuss this issue and consider referral for more formal genetic counselling 
if available. 
• Discussions should consider the risks of exposure both in utero and via breastfeeding on the child in 
relation to birth defects, neonatal complications and developmental or longer term effects. However, 
the benefits of medication should also be considered in relation to the potential for treating the 
mother’s current mental illness and/or preventing a relapse, acknowledging the impact such illness 
can have on the child as well as the mother and wider family. 
• Risks, wherever possible, should be individualised. In this regard, care should be taken in 
recommending switching a woman from a drug with known adverse effects in the perinatal period to 
one with perceived lower risk (which may in fact reflect a lack of data rather than evidence of safety), 
especially if there is evidence of efficacy of the former, but not the later, drug in the woman concerned. 
• The degree of risk is uncertain in relation to many of the elements that need to be considered when 
discussing the use of psychotropics in the perinatal period. It is important to explicitly acknowledge 
this uncertainty with women and their partners. Simply describing the size of the risk without putting 
this into the context of absolute risk rates can be misleading. 
• Care should be taken to avoid medical jargon when discussing risks and benefits. Care should also be 
taken that the biases of the clinician does not colour the description of the relevant risks and benefits 
of the various options. 
• Be aware that a woman may also be receiving information from multiple professionals and 
significant others, or have read out-dated or inaccurate information on the internet. 
• Women should be afforded the opportunity of discussing the issues around the use of psychotropics 
in the perinatal period broken down over more than one session, and again at any significant point of 
potential change in management. 
• Clinicians should carefully document a record of discussions regarding the use of psychotropics during 
the perinatal period. This is best done by providing the woman with a letter detailing in non-technical 
language, the discussion and conclusions reached, and copying this to all professionals involved, so 
that the record becomes a clinically and educationally useful, shared one. 
• In any discussion of potential adverse outcomes, the potential for inducing or exacerbating excessive 
worry or inappropriate guilt must be consideredaround risk of neonatal adaption syndromes and, for 
example, persistent pulmonary hypertension of the newborn (PPHN – see section ‘Teratogenicity’). 
|| Close to delivery, there needs to be consideration of whether there is any evidence that reduction/ 
discontinuation of medication will alter the risk of neonatal syndromes particular to the medication in 
question, taking into account the risks to the mother of doing so. 
|| For most women, the delivery date is not certain so the woman may be exposed to an ineffective 
dose for several weeks at a time when risks (e.g. of bipolar relapse) may begin to increase. 
|| There is no evidence on how long reduction/discontinuation would need to be for to reduce this risk, 
but 14 days may not be enough (Warburton et al., 2010). 
|| Plans to breastfeed should also be taken into account as this may mitigate discontinuation. 
|| As neonatal adaption syndromes are generally mild and transient, this issue is probably most 
relevant in pregnancies with known fetal problems such as IUGR or malformations. 
• During an admission to the maternity unit, consider the need for a specialist mental health nurse or 
an advocate where appropriate. The intrapartum period 
• In women with a severe mental illness, it is recommended that delivery should be in hospital. 
• Anticipate potential issues which might arise. 
• Midwives need to be aware of any medication issues, for example the need to stop lithium when the 
woman goes into labour, or any medication that might need to be started immediately following 
delivery, for example in a woman at risk of a postnatal episode. 
• Information needs to be provided as to when and how clinical staff on the maternity ward should 
seek psychiatric advice. 
• Information about potential risks of medication taken during pregnancy on the baby needs to be 
discussed with the relevant neonatologists. Postnatally and during breastfeeding 
• The WHO recommends that ‘infants should be exclusively breastfed for the first 6 months of life to 
achieve optimal growth, development and health’ (World Health Organisation, 2003). 
• Take care with any sedating medication especially in the postnatal period since excessive sedation 
can hinder baby care and breastfeeding. Although sedation can often resolve over a short period after 
starting a medication, alternative options may need to be considered. 
• Advise women against co-sleeping with their babies.  
• Where relevant, consider a discussion about the woman’s parenting capacity and the potential need 
for referral to Children and Families social services. Where a woman has significantly impaired social 
function and poor social support, consider discussing the risk of custody loss. 
• Breastfeeding women with mental illness should have rapid access to psychological therapies, but 
where illness is more severe, drug therapy may be an essential component of effective treatment. 
• Choose treatments for women who are breastfeeding with the lowest known risk and keep in mind 
that there is very limited knowledge about long-term neurodevelopmental outcomes. 
• A guide to the possible risk of breastfeeding while taking a particular drug is the relative infant dose 
(RID) – the daily amount of drug ingested by the infant during exclusive breastfeeding per kg 
bodyweight divided by the maternal daily dose per kg body weight. Information regarding this can be 
found in the Drugs and Lactation Database, 2016 
(https://www.nlm.nih.gov/pubs/factsheets/lactmedfs.html). 
• As in pregnancy, previous treatment response should guide future treatment choices. 
• Where there is no clear evidence base that one drug is safer during breastfeeding than another, the 
best option may be not to switch. 
• There is little clear evidence to support the discarding of breastmilk or timing of breastfeeding in 
relation to time of maternal drug administration. Such recommendations  could potentially add to the 
difficulties and challenges of establishing breastfeeding. 
• Monitor the infant for adverse effects such as (but not limited to) over sedation and poor feeding. 
• These recommendations in general apply to term, healthy infants. Great caution should be exercised 
in decisions around maternal psychotropic prescribing for breastfed premature or sick infants, and 
where the mother is taking more than one drug. 
 
Recommendations regarding discussion of the risks and benefits of psychotropics with women 
• Some degree of discussion is required for all women of childbearing potential being prescribed a 
psychotropic. 
• For women who are considering starting or extending their families the need for more extensive 
preconception counselling should be considered, ideally to be delivered by specialist perinatal mental 
health services for women with the highest or most severe risks (history of bipolar disorder or severe 
mental illness). 
• The main goal of discussions is to individualise the advice to the woman taking into consideration 
her particular history of illness, response to treatment, and attitudes to risk both to her and to the 
baby. 
• See ‘Scope and target’ for a framework described by NICE of the various risks and benefits that need 
to be considered in the discussions. 
• As discussed in ‘Risks of untreated illness in pregnancy’, women should also be aware not only of the 
known or potential risks of medication but also of the evidence that untreated illness in pregnancy may 
be associated with increased adverse effects for the woman herself, her pregnancy, 
and for infant outcomes. 
• Consideration should be given to providing information in a number of ways, for example in both 
verbal and written forms. 
|| There are a number of online resources (e.g. www. medicinesinpregnancy.org from UKTIS) that 
provide evidence-based and updated information to assist women in making informed decisions about 
treatment, although these do not remove the need for detailed individualised assessment and 
discussion of options with a clinician. 
• The nature and level of discussion regarding the risks and benefits of psychotropics in the perinatal 
period should be tailored to the needs of the woman and, where relevant and agreed by the woman, 
her partner. 
• Women may be concerned about the risk that any children they have may suffer from mental illness. 
It is therefore important to discuss this issue and consider referral for more formal genetic counselling 
if available. 
• Discussions should consider the risks of exposure both in utero and via breastfeeding on the child in 
relation to birth defects, neonatal complications and developmental or longer term effects. However, 
the benefits of medication should also be considered in relation to the potential for treating the 
mother’s current mental illness and/or preventing a relapse, acknowledging the impact such illness 
can have on the child as well as the mother and wider family. 
• Risks, wherever possible, should be individualised. In this regard, care should be taken in 
recommending switching a woman from a drug with known adverse effects in the perinatal period to 
one with perceived lower risk (which may in fact reflect a lack of data rather than evidence of safety), 
especially if there is evidence of efficacy of the former, but not the later, drug in the woman concerned. 
• The degree of risk is uncertain in relation to many of the elements that need to be considered when 
discussing the use of psychotropics in the perinatal period. It is important to explicitly acknowledge 
this uncertainty with women and their partners. Simply describing the size of the risk without putting 
this into the context of absolute risk rates can be misleading. 
• Care should be taken to avoid medical jargon when discussing risks and benefits. Care should also be 
taken that the biases of the clinician does not colour the description of the relevant risks and benefits 
of the various options. 
• Be aware that a woman may also be receiving information from multiple professionals and 
significant others, or have read out-dated or inaccurate information on the internet. 
• Women should be afforded the opportunity of discussing the issues around the use of psychotropics 
in the perinatal period broken down over more than one session, and again at any significant point of 
potential change in management. 
• Clinicians should carefully document a record of discussions regarding the use of psychotropics during 
the perinatal period. This is best done by providing the woman with a letter detailing in non-technical 
language, the discussion and conclusions reached, and copying this to all professionals involved, so 
that the record becomes a clinically and educationally useful, shared one. 
• In any discussion of potential adverse outcomes, the potential for inducing or exacerbating excessive 
worry or inappropriate guilt must be considered. 
 
Benefits and harms associated with individual medications 
The effects of a medication on the ability to conceive, or on a pregnancy and its outcome (e.g. 
miscarriage, live birth, still birth or intrauterine death), and on the developing fetus, are reviewed 
below and should always be taken into account when prescribing in pregnancy or to women who wish 
to breastfeed. 
 
Antidepressants 
Exposure to antidepressants in pregnancy has increased over recent decades, with a registry study 
from Denmark reporting a 16-fold increase from 0.2% of pregnancies in 1997 to 3.2% in 
2010 (Kjaersgaard et al., 2013). 
Although there are many large studies examining the reproductive safety of these drugs, with one 
recent study including 128,950 exposures (Huybrechts et al., 2015), any specific impact of 
antidepressants independent of maternal depression is still unclear. 
Most recent, large-scale research focusses on SSRIs. The popular belief that tricyclics may be safer 
than SSRIs was challenged by a large study by Reis and Kallen (2010), demonstrating that outcomes 
after exposure to tricyclics (albeit predominantly clomipramine) are, for most measures (preterm 
birth, low birthweight, hypoglycaemia, respiratory diagnoses, low Apgar score, jaundice and cardiac 
malformations), not significantly different than after exposure to SSRIs or other antidepressants (Reis 
and Kallen, 2010). It is important to note, however, that differences in the nature of the women (and 
their depression) who are prescribed a tricyclic versus an SSRI may confound this finding. In addition, 
not all studies address the confounder effects of depression per se, leaving the conclusions on the 
direct adverse consequences uniquely attributable to antidepressants still unclear. 
Given that guidelines tend to recommend SSRIs as first-line drug treatments for depression (NICE, 
2009), including in pregnancy in antidepressant naive women (NICE, 2015a), these will largely be the 
focus of this section (note bupropion is covered in ‘Smoking/nicotine dependence’). 
 
Effects on ability to conceive. There are no data suggesting antidepressants impact on the ability of 
women to conceive, although there is some evidence that they may affect male sperm count and 
morphology (Akasheh et al., 2014). 
 
Pregnancy outcomes. A recent review summarised the literature relating to antidepressant impact on 
pregnancy outcome (Ross et al., 2013) and, although including 23 studies, it was notable that only six 
studies made any attempt to control for depression. It found no significant impact of AD exposure on 
rates of spontaneous abortion; a small impact on gestational age at delivery (0.45 weeks earlier); a 
modest impact on Apgar scores (0.37 lower at 1 min, 0.18 at 5 min); and a modest impact on 
birthweight (74 g lower), although this last was not significant if the comparison group was women 
with depression. However, there are conflicting data and not all antidepressants may be associated 
with the same magnitude of risk. 
Drugs that block serotonin uptake, such as many antidepressants, are associated with increased risks 
of bleeding (NICE, 2009). There have been reports of particularly third trimester exposure to 
antidepressants being associated with an increased risk of postpartum haemorrhage (Bruning et al., 
2015; Hanley et al., 2016). However, the data are limited and the magnitude and clinical significance 
of the risk uncertain. 
  
Teratogenicity. Studies first reported an increased risk of cardiac defects with paroxetine exposure in 
2006 (GSK, 2013 http:// www.gsk.com/media/resource-centre/paroxetine/paroxetineand- 
pregnancy.html; (Kallen and Otterblad, 2007), indicating an absolute risk for cardiac defects of around 
1.5–2% in babies born to mothers who took paroxetine compared with a rate of around 1% in the 
general population. Subsequent studies have implicated other antidepressants, including all 
commonly used SSRIs and clomipramine (Reis and Kallen, 2010; Shen et al., 2017). Another large study 
that adjusted for confounding factors found that small but significantly increased risks of cardiac 
malformations with fluoxetine (ventral septal defects) and paroxetine (right ventricular outflow tract 
defects), were no longer significant after adjustment for depression-associated confounders, such as 
smoking, other psychiatric medication and fetal alcohol syndrome (Malm et al., 2011). Similarly, a very 
large study that also adjusted for depression-associated confounders found no substantial increase in 
the risk of cardiac malformations (Huybrechts et al., 2014a). 
A specific problem that has been associated with serotonergic antidepressant use in mid to late 
pregnancy PPHN, a severe condition with a high mortality. Although initial reports suggested an 
approximate six-fold increase, equating to 6–12/1000 births to SSRI exposed pregnancies compared 
to 1–2/1000 births in the general population (Chambers et al., 2006), a recent study combining data 
from a number of Scandinavian registries found the absolute risk to be small and more modest 
(approximate 1.5 fold increase from around 20 per 10,000 births to around 30) and this was no longer 
significant when confounders were taken into account (Huybrechts et al., 2015). 
In general, for all adverse outcomes, studies which have taken account of the underlying depression 
and other confounding factors, find smaller effects potentially attributable to antidepressant 
medication. 
 
Neonatal and developmental problems. The data appear to support the existence of a neonatal 
behavioural syndrome following in utero exposure to antidepressants, including irritability, constant 
crying, jitteriness, vomiting, shivering, increased tone, and eating and sleeping difficulties. Moses-
Kolko et al. (2005) identified nine cohort studies, five of which defined a neonatal behavioural 
syndrome, and found it occurs three times more often in neonates exposed to SSRIs in late pregnancy 
(30% in SSRI exposed, 10% in general population) (Moses-Kolko et al., 2005). They also found that 
admission to a special care baby unit was 2–3 times more common in the SSRI exposed neonates, 
although it is possible that this may be a precaution in some cases to enable monitoring rather than 
being indicative of symptoms. A recent meta-analysis of 12 studies found a significant five-fold 
increased risk (5–78% risk in exposed vs 0–41% in non-exposed infants) of postnatal adaption 
syndrome or respiratory distress and tremors in infants exposed to antidepressants before delivery 
(Grigoriadis et al., 2013). However, as per the evidence for teratogenicity, there is also the possibility 
that these adverse neonatal outcomes are not attributable to antidepressants toxicity or withdrawal 
but rather to the underlying maternal disorder or concurrent exposures. One naturalistic observation 
study compared the outcomes of neonates exposed to SSRIs in the last 14 days of pregnancy and 
neonates exposed in pregnancy but not in the last two weeks, and found an increased risk of neonatal 
respiratory distress in the last-exposed group (Warburton et al., 2010). However, when controlled for 
maternal illness severity, reducing exposure to SSRIs at the end of pregnancy did not improve neonatal 
health. 
Data on long-term effects of antidepressant exposure in utero are particularly sparse. One study of 
the Danish National Birth Cohort, which compared women on antidepressants, women with 
depression in pregnancy who did not take antidepressants and women with no depression or 
antidepressant use, found a small developmental delay in gross motor function related to medication 
in late pregnancy, however, there were no differences between groups by 19 months (Pedersen et al., 
2010). 
There have been a number of studies that have suggested a relationship between in utero 
antidepressant exposure and both ADHD and ASD with suggestions of around a two-fold increased 
rate of ASD from a background rate of approximately 0.7–1% (Boukhris et al., 2016; Croen et al., 2011; 
Figueroa, 2010; Man et al., 2015). However, there have also been large cohort studies which failed to 
find such associations (Castro et al., 2016; Laugesen et al., 2013). The discrepancy may be attributed 
to potential confounding of the maternal indication for taking antidepressant in that, although some 
studies have still found an association (albeit reduced in magnitude) after controlling for maternal 
depression (Boukhris et al., 2016), in others the association is no longer significant (Clements et al., 
2015). This explanation is also supported by two other observations. The first is that in a large Finnish 
cohort study, prenatal exposure to SSRIs was associated with an increased risk of depression (8% vs 
2% in non-exposed children), but not ASD or ADHD, in early adolescence. A potential, at least partial, 
explanation for this observation is shared genetic risk factors. The second observation is that a meta-
analysis has suggested that there is a significant increased risk of ASD in children whose mothers were 
exposed pre-conception to SSRIs (Kaplan et al., 2016). Although there may still be a plausible biological 
mechanism for pre-conception maternal exposure to lead to a developmental problem in their 
offspring, as the authors of the meta-analysis point out, confounders by indication for the SSRI, 
including shared genetic risk, cannot be ruled out. Taken all together, there is uncertainty about 
whether in utero exposure increases the risk of ASD or ADHD and reported findings may well result 
from confounding factors. 
More reassuringly, at least one study has indicated potential long-term benefit to the children of 
mothers with depression in pregnancy being treated with antidepressant medication. Data from 
49,000 women examined the impact of prenatal exposure to SSRIs on behavioural problems at aged 
7, finding that untreated prenatal depression was associated with an increased risk of problem 
behaviour in the children (hyperactivity, inattention and peer problems) but, crucially, this increased 
risk was not seen in the children whose mothers took antidepressants in pregnancy (Grzeskowiak et 
al., 2015). This study confirms the abundant evidence that maternal depression in pregnancy increases 
the risk of psychopathology and other social adversity in the offspring into adolescence and young 
adulthood (Plant et al., 2015b), and supports previous assumptions that treating depression reduces 
this risk. 
Breastfeeding. Most evidence regarding the safety of antidepressants during breastfeeding comes 
from single case reports and case series, only a minority of which include a control population. Where 
larger samples are reported, they usually include a mix of exposed drugs, and indirect measures of 
infant drug exposure, if measured at all. Moreover, studies of breastfed infants are often confounded 
by antenatal exposure to the same drug, which may act as a ‘loading dose’, increasing the risk of early 
adverse effects. Few studies report on depression-associated confounders, such as maternal smoking, 
alcohol or substance use, or on infant characteristics, such as weight. Lastly, there is a paucity of 
studies examining the long-term effects of drug exposure through breast milk on infant development. 
Where this has been reported, it is usually only within the first 12 months of life. 
Overall, SSRIs with lowest reported levels of exposure or adverse physical effects include sertraline 
and paroxetine (Berle and Spigset, 2011; Davanzo et al., 2011; Orsolini and Bellantuono, 2015). Given 
the greater risks of side effects and withdrawal problems with paroxetine compared with other SSRIs 
(Cleare et al., 2015), sertraline would be the preferred treatment option. 
Conclusions/Recommendations 
• The majority of data on the effects of antidepressants are confounded by many uncontrolled 
variables, including the impact of depression itself. 
• Antidepressants, when studied as a group, may have a small effect on some pregnancy outcomes 
(gestational age,  Apgar score) but these may be due to residual confounding  issues and in addition 
may not be clinically significant. 
• Antidepressants that block serotonin uptake may be associated with an increased risk of postpartum 
haemorrhage, but the magnitude and clinical significance of this risk is uncertain. 
• There have been concerns about antidepressant (mainly SSRIs and possibly particularly paroxetine) 
exposure in utero being associated with cardiac malformations. However, this may not be the case 
once all confounders are taken into account. 
• Although the risk of PPHN in babies exposed in utero to SSRIs is increased, the absolute risk is low. 
• There is some evidence of neonatal effects following late pregnancy exposure to SSRIs, particularly 
respiratory distress and neonatal behavioural syndrome. 
• Some studies have reported an association between exposure to antidepressants in utero and an 
increased risk of ASD or ADHD later in childhood. However, the data are mixed with other studies 
suggesting the association may be due to confounding. 
• Babies born to mothers with depression and treated with antidepressants during pregnancy may 
have better longer term emotional and behavioural development compared to babies born to mothers 
with depression that was untreated. 
• Sertraline has a low rate of reported adverse effects on breastfed babies and for new episodes of 
depression may be appropriate. However, the choice of antidepressant should be guided by the same 
principles as choice during pregnancy, for example taking into account a woman’s previous response 
to medication. Careful monitoring of  the infant is always important. 
• Recommendations regarding the use of antidepressants in depression and anxiety are described in 
sections on ‘Management of depression’ and ‘Management of anxiety disorders and insomnia’, 
respectively. 
 
Anxiolytics/hypnotics 
This section considers benzodiazepines, ‘Z-drugs’ (zolpidem, zopiclone and zaleplon), buspirone, beta-
blockers, pregabalin and gabapentin. 
There is much uncertainty about the effects of anxiolytic or hypnotic medications on fertility, in 
pregnant or breastfeeding mothers, or on subsequent infantile and childhood development. A 
systematic review (including 43 controlled studies) of possible associations between maternal 
antidepressant or anxiolytic drug treatment and childhood neurodevelopmental measures 
emphasised the inconsistent nature of individual study findings and stresses the need for further well-
designed observational studies (El et al., 2014). Much of the reported literature does not control for 
important confounders such as the type and severity of maternal illness. 
 
Effects on ability to conceive. There are no human data in either men or women regarding the effects 
of anxiolytic and hypnotic drugs on fertility. 
Pregnancy outcomes. Beta-blockers cross the placental barrier and can increase insulin levels and 
decrease glucagon levels, with a consequent risk of hypoglycaemia in new-born infants (Bricelj, 1999). 
A pharmaco-epidemiological study found that infants exposed to beta-blockers in the third trimester 
of pregnancy had an approximately three-fold risk of hypoglycaemia (8% vs 2% risk in unexposed 
infants) and two-fold risk of feeding problems (9% vs 5%) (Davis et al., 2011). Additionally, a Danish 
population study found beta-blocker exposure in pregnancy to be associated with around a two-fold 
increased risk of ‘small for gestational age’ (18% vs 10% for unexposed infants), preterm birth (28% vs 
12%) or perinatal mortality (1.8% vs 0.7%) (Meidahl et al., 2012). However, because maternal 
hypertension itself increases the risk of intrauterine growth restriction (Lin et al., 2015), causal analysis 
is complex and any contribution of beta-blocker exposure to these outcomes remains unquantified. 
Overall, the available data do not suggest that gestational beta-blocker exposure increases the risk of 
preterm delivery (Magee and Duley, 2003). Data on rates of spontaneous abortion, stillbirth and 
neurodevelopmental outcomes are too limited to permit a risk assessment. 
Zolpidem crosses the placental barrier (Juric et al., 2009). A population-based study from Taiwan of 
2,497 mothers taking zolpidem during pregnancy compared with 12,485 mothers on no medication 
found a 40–70% increased risk of preterm delivery (10% vs 6% for unexposed infants), low birthweight 
(8% vs 5%) and Caesarean section (47% vs 33%) (Wang et al., 2010). 
However, there was no adjustment for the indication for which the zolpidem was being prescribed. 
There are limited other data on the effects of anxiolytics and hypnotics on pregnancy outcomes. 
 
Teratogenicity. Retrospective case reports and cohort studies have previously found an association 
between benzodiazepine exposure and oral cleft (Dolovich et al., 1998). However, this finding has not 
been replicated in prospective cohort studies (Wikner et al., 2007). Additionally, a UK population-
based cohort study suggests first trimester exposure to benzodiazepines or non-benzodiazepine 
hypnotics is not associated with an increase in major congenital anomalies (Ban et al., 2014). 
Little is known about the safety of gabapentin or pregabalin in pregnant women, but both drugs are 
eliminated unchanged in urine and their plasma levels should be expected to decline during pregnancy 
(Reimers, 2014). A Norwegian birth registry study detected no increase in the rate of congenital 
malformations among infants of women exposed to pregabalin during pregnancy (and no reported 
malformations in infants exposed to gabapentin), when compared to a control group of woman with 
epilepsy who were not undergoing anticonvulsant treatment (Veiby et al., 2014). However, an 
increased risk of major malformation was associated with pregabalin exposure in a recent prospective 
cohort study, although the small number of exposed pregnancies and potential confounding may 
account for the findings (Winterfeld et al., 2016). 
There are no human data regarding the safety of buspirone in pregnant women. 
Information is limited about the safety of so-called ‘Z-drugs’ in pregnant women, although a national 
birth registry study indicates that in utero exposure to zopiclone, zolpidem or zaleplon is not 
associated with an increased risk of congenital malformations (Wikner and Kallen, 2011). 
A meta-analysis has suggested that gestational beta-blocker exposure may be linked to increased risks 
of cleft lip and/or palate and neural tube defects in the infant (Yakoob et al., 2013), although these 
findings remain to be confirmed. This review also suggested a possible increased risk of congenital 
heart defects among infants of women who were treated with beta-blockers in pregnancy (Yakoob et 
al., 2013). However, increased rates of cardiovascular malformation have been observed with other 
antihypertensive therapies (Caton et al., 2009). This association may therefore reflect a physiological 
effect of lowering the maternal lblood pressure rather than a drug-specific teratogenic effect, or may 
be causally related to the underlying maternal hypertension (Ramakrishnan et al., 2015). 
 
Neonatal and developmental problems. Little is known about the effects of in utero exposure to 
anxiolytic drugs on infantile development. An early longitudinal case-control study suggested that 
exposure to meprobamate or chlordiazepoxide (n = 1870) had no adverse effects (Hartz et al., 1975), 
but a small (n = 17) follow-up study of children exposed to various benzodiazepines suggested early 
(up to 18 months) motor and wider developmental delay (Laegreid et al., 1992; Viggedal et al., 1993). 
A more recent Danish regional prescription register study suggested in utero benzodiazepine (and 
antidepressant and antipsychotic) exposure is possibly associated with an increased risk of delayed 
psychomotor development (Mortensen et al., 2003). This is consistent with a longitudinal study (n = 
184), which suggests that exposure to concomitant benzodiazepines during antidepressant treatment 
in pregnant women may increase the risks of lower motor scores, higher ‘CNS stress signs’ across the 
first postnatal month, and of lower self-regulation and higher arousal in the first 2 weeks after delivery 
(Salisbury et al., 2016). 
Use of beta-blockers near term may result in neonatal betaadrenoceptor blockade leading to neonatal 
bradycardia, hypotension and hypoglycaemia (Bateman et al., 2016). Neonatal respiratory distress has 
also been reported (Magee and Duley, 2003). 
 
Breastfeeding. Potential consequences of benzodiazepine administration in breastfeeding mothers 
are not clearly established but a prospective cohort study suggests neonatal adverse events are 
uncommon (1.6% of infants) (Kelly et al., 2012). However, analysis of a French pharmacovigilance 
database led the authors to suggest benzodiazepines should be used cautiously in breastfeeding 
mothers (Soussan et al., 2014). Potential adverse consequences vary between drugs (Newport et al., 
2008). Flimsy evidence suggests diazepam and chlordiazepoxide may be preferable to other 
benzodiazepines (Ito et al., 1993). 
Gabapentin levels in breast milk are similar to those in maternal plasma (Reimers, 2014), which might 
suggest that close monitoring of babies breastfed by mothers taking gabapentin is advisable. 
A small study suggests zaleplon crosses into breast milk but only in small quantities, and in rapidly 
declining levels after single- dose administration (Darwish et al., 1999). 
 
Conclusions/Recommendations 
• There are very limited data pertaining to fertility effects of anxiolytics/hypnotics in humans. 
• Zolpidem may increase the risk of adverse pregnancy outcomes including preterm delivery and low 
birthweight of infants, though the magnitude of this risk if it exists is uncertain. 
• There is no convincing evidence in the available data of an increased risk of birth defects associated 
with benzodiazepines or ‘Z-drugs’. 
• There are limited data suggesting benzodiazepine exposure in utero may be associated with delayed 
psychomotor development. 
• Beta-blocker exposure in pregnancy has been associated with a number of possible risks, although 
the data may be confounded by the maternal indication for the treatment. 
• There are very limited data regarding the risks of gabapentin, pregabalin and buspirone exposure in 
utero. 
• Hypnotics and anxiolytics cross into breast milk so close monitoring of babies is required in mothers 
who are breastfeeding and taking these medications. 
• Recommendations around the use of anxiolytics and hypnotics is described in ‘Management of 
anxiety disorders and insomnia’ 
 
Antipsychotics 
Antipsychotics are increasingly prescribed in pregnancy; most commonly for depression, followed by 
bipolar disorder and schizophrenia (Petersen et al., 2016; Toh et al., 2013). The summary below is 
based on evidence from systematic reviews (Coughlin et al., 2015; Gentile, 2010; NICE, 2015a; Terrana 
et al., 2015) and more recent original studies (Cohen et al., 2016; Petersen et al., 2016; Vigod et al., 
2015). Studies up to 2016 included a total of around 4000 women exposed to a range of antipsychotics 
in pregnancy, and the evidence was significantly expanded in 2016 with the publication of a large US 
study on congenital malformations among >9000 women exposed to atypical antipsychotics and 700 
women exposed to typical antipsychotics (Huybrechts et al., 2016). 
Women who take antipsychotics in pregnancy are more likely to be obese, smoke, drink alcohol, use 
drugs, use other medications and have pre-existing diabetes and hypertension than pregnant women 
in the general population (NICE, 2015a; Petersen et al., 2016; Vigod et al., 2015). In general, studies 
that compare women exposed to antipsychotics in pregnancy to healthy unexposed women report 
moderately increased risks for several adverse maternal and infant outcomes (including congenital 
malformations, preterm birth, fetal growth abnormalities and poor neonatal adaptation) (Boden et 
al., 2012b; Habermann et al., 2013; Reis and Kallen, 2008; Sadowski et al., 2013). By contrast, the few 
studies that used a comparison group of women with psychiatric illness but unexposed to 
antipsychotics (Boden et al., 2012a; Lin et al., 2010; NICE, 2015a; Petersen et al., 2016), or studies that 
adequately controlled for confounding (Vigod et al., 2015), report few associations between 
antipsychotics and adverse maternal or infant outcomes. Overall, there is little difference in fetal risks 
between first- and second-generation antipsychotics (FGA and SGAs), or between individual 
antipsychotics, but human pregnancy safety data for some individual antipsychotics are limited. In 
utero exposure data are most available for olanzapine and quetiapine (more than 800 exposed cases 
each) followed by risperidone and haloperidol (around 400 exposed cases each), with more limited 
data for clozapine and aripiprazole (Habermann et al., 2013; Larsen et al., 2015; NICE, 2015a; Vigod et 
al., 2015). It should, however, be noted that not all exposures occurred in the first trimester and 
evidence to support a lack of structural teratogenesis or increased risk of miscarriage may therefore 
be less strong. 
Placental passage of antipsychotics is incomplete but varies between drugs. Among four 
antipsychotics studied in one sample, highest rates were found for olanzapine, then haloperidol, then 
risperidone, with the lowest rate for quetiapine (Newport et al., 2007a). 
 
Effects on ability to conceive. All FGAs and some SGAs 
(especially risperidone and amisulpride) can cause hyperprolactinaemia and impaired fertility (Haddad 
and Wieck, 2004). Switching to a prolactin-sparing antipsychotic may lead to unwanted pregnancy. A  
woman planning a pregnancy and stopping a prolactin- raising antipsychotic may still have difficulties 
conceiving owing to other factors, such as stress, obesity and illness-related endocrine mechanisms. 
In men, hyperprolactinaemia can lead to loss of libido and reduction and impairment in 
spermatogenesis (De et al., 2003). 
 
Pregnancy outcomes. There is a concern that antipsychotics, particularly SGAs associated with 
metabolic disturbance may increase the risk of gestational diabetes mellitus (GDM), obesity and 
gestational hypertension, conditions which are in turn associated with adverse maternal and neonatal 
outcomes such as fetal growth abnormalities, preterm birth and congenital malformations. Studies 
comparing women on antipsychotics with healthy controls find a nearly two-fold increased risk of 
GDM (approximately 4% vs 2%) (Boden et al., 2012a; Reis and Kallen, 2008), but studies which employ 
a disease matched control group of psychiatrically ill unexposed women find no significant risk 
increase in GDM or gestational hypertension (Petersen et al., 2016; Vigod et al., 2015). The risk of 
GDM appears similar for olanzapine or clozapine versus other antipsychotics (Boden et al., 2012b; 
Vigod et al., 2015). 
Some studies have reported that antipsychotics may be associated with an increased risk of small for 
gestational age babies (12% vs 8%), low birthweight babies (by 50–100 g) and preterm births (on 
average 2 days shorter gestation) but few differences are found between medicated and unmedicated 
psychiatrically ill women (Boden et al., 2012a; Coughlin et al., 2015; Lin et al., 2010; Petersen et al., 
2016; Terrana et al., 2015; Vigod et al., 2015). One systematic review reported similar risks for preterm 
birth for SGAs and FGAs (Coughlin et al., 2015). A specific association with macrosomia (Boden et al., 
2012b) and being large for gestational age (Gentile, 2010; Newham et al., 2008) has been suggested 
for SGAs, though other studies have not observed this (Boden et al., 2012c; Newport et al., 2007b). 
There is no evidence for an increased risk of stillbirth or spontaneous miscarriage (Coughlin et al., 
2015; Habermann et al., 2013; McKenna et al., 2005; NICE, 2015a; Terrana et al., 2015; Vigod et al., 
2015). 
Teratogenicity. Existing evidence suggests that FGAs and SGAs are not major teratogens and, for those 
for which human data are available, few specific associations have been identified (Ennis and Damkier, 
2015; NICE, 2015a; Terrana et al., 2015). However, there are limited data on individual antipsychotics, 
with most first trimester exposure data available for olanzapine (1500 exposures) and quetiapine (440 
exposures) (Ennis and Damkier, 2015; Vigod et al., 2015), and more recently for risperidone and 
aripiprazole (Huybrechts et al., 2016).  
Systematic reviews estimate a 60% to two-fold increased risk for major congenital malformations 
among antipsychoticexposed infants (Coughlin et al., 2015; Terrana et al., 2015), with an estimated 
absolute risk increase of 13/1000 from a background rate of 20–40/1000 (NICE, 2015a). One 
systematic review reported similar risks for major congenital malformations following exposure to 
FGAs and SGAs (NICE, 2015a). The commonest reported association is with cardiac defects (Coughlin 
et al., 2015), but such associations, like with cardiac septal defects, may be attributable to detection 
bias (Habermann et al., 2013; Reis and Kallen, 2008). 
A recent national US cohort study of around 1.36 million women with a livebirth delivery in 2000–
2010 found that the risk of any congenital malformations, and specifically of cardiac malformations, 
was not meaningfully increased for women exposed to atypical antipsychotics (n = 9258) or typical 
antipsychotics (n = 733) when compared to unexposed women after adjusting for key confounders 
(Huybrechts et al., 2016). For individual antipsychotics, the authors found no increased risk following 
exposure to quetiapine (n = 4221), olanzapine (n = 1394), aripirazole (n = 1756) or ziprasidone (n = 
697). They did find an unexpected small increased risk following risperidone exposure (n = 1566) of 
any malformation by around 25% from around 3% in unexposed infants to 5% in those exposed and 
for cardiac malformations from 1% to 2%. The authors argue that these findings for risperidone 
indicate a possible safety signal that requires clarification in future studies (Huybrechts et al., 2016). 
Other studies that have used psychiatric controls, or that controlled for confounding factors, have 
found no significant increase in congenital malformations (Boden et al., 2012a; Cohen et al., 2016; 
Petersen et al., 2016; Vigod et al., 2015), although risk estimates were imprecise. Earlier studies 
reported no significant increase in risk for major malformations with butyrophenones (mainly 
haloperidol) (Diav- Citrin et al., 2005) and phenothiazines (Slone et al., 1977). 
 
Neonatal and developmental problems. Extrapyramidal and withdrawal symptoms have been 
described in neonates following late pregnancy exposure to antipsychotic medication (Gentile, 
2010; Habermann et al., 2013; Sadowski et al., 2013). The US Food and Drug Administration 
(http://www.fda.gov/Drugs/ DrugSafety/ucm243903.htm) and the UK’s Medicines and 
Health Care Products Regulatory Authority (https://www.gov.uk/ drug-safety-update/antipsychotics-
risk-of-extrapyramidaleffects- or-withdrawal-symptoms-in-newborns) have issued relevant safety 
labelling, and recommended relevant monitoring for neonates. However, studies that adequately 
controlled for confounding did not find a specific association between antipsychotic exposure and 
poor neonatal adaptation (Petersen et al., 2016; Vigod et al., 2015). 
 
There is very little evidence on the long-term neurodevneurodevelopmental outcome of infants 
exposed to antipsychotics in pregnancy. One small study found neuro-motor delay at 6 months in 
infants exposed to antipsychotics compared to infants exposed to antidepressants or unexposed 
infants (Johnson et al., 2012). Another study found development delay at 2 months but not at 12 
months among infants of mothers with schizophrenia treated with antipsychotics (SGAs or sulpiride) 
compared to infants of healthy, unexposed mothers (Peng et al., 2013). 
 
Breastfeeding. Breastfeeding while on clozapine is contraindicatedowing to the risk of infant 
agranulocytosis and seizures (NICE, 2015a; Parikh et al., 2014; Uguz, 2016). Many FGAs (haloperidol, 
perphenazine, trifluoperazine and chlorpromazine) are excreted in breast milk in small amounts, with 
an estimated RID of <10% (Moretti, 2009; Parikh et al., 2014). A 2016 review of the safety of SGAs in 
breastfed infants identified 37 studies with 210 exposed infants (including 170 exposed to olanzapine) 
(Uguz, 2016). The evidence suggested low RID values for olanzapine and quetiapine, moderate RID 
values for risperidone and aripiprazole and high RID values for amisulpride. No serious adverse effects 
were reported. There were case reports of drowsiness, irritability, motor abnormalities and poor 
feeding following exposure to these drugs and infants should be monitored appropriately especially if 
at high risk (e.g. premature or LBW infants). 
There were a few case reports of neurodevelopmental delay in infants exposed to antipsychotics in 
breastmilk (Gentile, 2008; Parikh et al., 2014), but these were not controlled studies and the effect of 
the underlying illness was not taken into account. There is a lack of data on long-term 
neurodevelopmental outcomes. Conclusions/Recommendations 
• There are now more published safety data in pregnancy 
for SGA than FGA antipsychotics. 
|| For SGAs there are most reproductive safety data for quetiapine, olanzapine and risperidone, with 
more limited data for clozapine, aripirazole and ziprasidone  
|| For FGAs there are most safety data for haloperidol. 
|| Quetiapine has a relative low rate of placental passage 
|| This should be taken into account alongside the other factors influencing choice of medication in 
pregnancy discussed in ‘Using medication in the perinatal period’. 
• Once confounders are taken into account there is little evidence of significant risk to maternal and 
infant outcomes for FGAs and SGAs. There is a possible safety signal for a small increased risk of 
malformations following in utero exposure to risperidone. Not all outcomes have been adequately 
studied and an increased risk cannot be completely ruled out. 
• Prolactin elevating antipsychotics impair the fertility of women and men. 
• The risk of GDM may be increased by antipsychotics and enhanced diabetes screening for all women 
prescribed antipsychotics (with oral glucose tolerance test as the gold standard) is advised. 
• SGAs may be associated with increased birthweights of babies. 
• There are suggestions that antipsychotic exposure in utero may be associated with neuro-motor 
developmental delays but the limited nature of the data makes drawing conclusions in this regard 
difficult and longer term data are lacking. 
• Switching medication is generally not advised due to the risk of relapse. Consider using the 
antipsychotic that has worked best for the woman after discussion of benefits and risks. 
• Monitor any baby closely who was exposed near delivery or is breastfed by a mother taking 
antipsychotics. 
• Breastfeeding while on clozapine is contraindicated. 
• Recommendations regarding the use of antipsychotics in schizophrenia and bipolar disorder is 
describe in ‘Management of schizophrenia and psychosis’ and ‘Management of bipolar disorder’, 
respectively. 
  
Lithium 
Despite the frequency of its use in psychiatric practice over many decades, the body of evidence on 
reproductive safety is smaller for lithium than for many other established drugs prescribed for mood 
disorders. 
  
Effects on ability to conceive. Lithium is not known to have significant effects on female fertility but 
may inhibit sperm motility (Raoof et al., 1989). 
  
Pregnancy outcomes. The available data are too few to draw any conclusions regarding effects on 
spontaneous abortion rates, fetal growth in utero or risk of preterm delivery. 
 
Teratogenicity. Two meta-analyses and one case control study have provided conflicting conclusions 
as to whether there is a small increase in the overall rate of major congenital malformations after first 
trimester lithium exposure (Diav-Citrin et al., 2014; McKnight et al., 2012; NICE, 2015a). Much 
attention has focussed on the rare (prevalence in the general population 1:20,000) but severe 
cardiovascular anomaly of the Ebstein type because the uncontrolled lithium baby register reported 
an increase of its prevalence to 2.7% (Weinstein, 1980). The methodological flaws of the register and 
the low number of Ebstein cases in subsequent studies suggest that, if there is any effect, it is likely to 
be much smaller, and that any effect estimates have to be regarded as unreliable (Diav-Citrin et al., 
2014; McKnight et al., 2012; NICE, 2015a). Indeed, the most recent and largest surveillance study of 
5.6 million births identifying 173 cases of Ebstein’s anomaly, unexplained by other causes, found an 
association with maternal mental health problems but not with lithium exposure (Boyle et al., 2016). 
 
Neonatal effects. There are no systematic data in this area. Neurodevelopmental effects. Small studies 
find no gross mental anomalies in children exposed to lithium in pregnancy compared to their 
unexposed siblings at age six (Schou, 1976). 
 
Breastfeeding. The RID estimates of lithium vary widely with values of up to 42% being reported (Drugs 
and Lactation Database, 2016: https://www.nlm.nih.gov/pubs/factsheets/lactmedfs. html). Infant 
serum levels can reach up to 50% of the maternal value and cases of lithium intoxication and other 
adverse effects have been reported (Drugs and Lactation Database, 2016), although there are case 
reports of successful breastfeeding by women taking lithium with careful monitoring of infant lithium 
levels (Bogen et al., 2012; Viguera et al., 2007a).  
 
Conclusions/Recommendations 
• There are no known effects of lithium on fertility in females. 
• Too little is known about the effects of lithium on pregnancy outcomes of spontaneous abortion, 
birthweight and gestational length to draw any conclusions. 
• Due to the small volume of data, existing evidence cannot exclude an effect of lithium on overall 
malformation rate, or cardiovascular anomalies in particular. However, if a risk exists, it is likely to be 
small. 
• There are no systematic data regarding neonatal effects of lithium exposure. 
• There are limited data suggesting no effects of lithium on neurodevelopment. 
• Significant amounts of lithium pass into breast milk. 
• Recommendations regarding the use of lithium in bipolar disorder are made in ‘Management of 
bipolar disorder’. 
 
Antiepileptic mood stabilisers 
Evidence relating to the reproductive safety of antiepileptic drugs (AEDs) almost exclusively comes 
from studies of women with epilepsy. 
 
Endocrine and effects on ability to conceive. Women with epilepsy using valproate have an increased 
rate of polycystic ovary syndrome/ovaries (Hu et al., 2011; Svalheim et al., 2015). However, evidence 
that this applies to women with bipolar disorder is lacking (Reynolds-May et al., 2014). Valproate 
treatment is reported to be associated with adverse spermatogenesis in men (Hamed et al., 2015). 
 
Carbamazepine and lamotrigine do not appear to cause reproductive endocrine disorders (Svalheim 
et al., 2015). However, by reducing the efficacy of oral and parenteral contraceptives, 
carbamazepine increases the risk of unintended pregnancies. 
 
Pregnancy outcomes. There are limited data in this area. It is important to note that a diagnosis of 
epilepsy is associated with a range of adverse obstetric outcomes, unrelated to AED use (Viale et al., 
2015) and that the effect of different drugs may be very different. Current evidence suggests that the 
use of AEDs in pregnancy is not associated with still-birth (Bech et al., 2014; Viale et al., 2015), but in 
high doses their use is associated with a small increased rate of spontaneous abortions (16% in women 
taking AEDs vs 13% in those not) (Bech et al., 2014). AEDs in pregnancy are also associated with a small 
(<50% increase) but significant increased risk of some obstetric complications (postpartum 
haemorrhage, induction of labour, admission to neonatal intensive care, low birthweight) over and 
above that associated with epilepsy (Viale et al., 2015), although the data that this estimate are based 
on are not fully controlled for all potential confounders. Multiple AED drug treatment appears to 
increase risks (Viale et al., 2015). 
 
Teratogenicity. Early pregnancy exposure to valproate is associated with an approximately three-fold 
increase in the rate of major congenital malformations (from around 3% to 8–11%) (Meador et al., 
2008; NICE, 2015a). Significant associations have been reported for spina bifida (an approximate 13-
fold increased risk from approximately 0.09% in the general population (Khoshnood et al., 2015) to 
between 1% and 2%), atrial septal defects, cleft palate, hypospadias, polydactyly and craniosynostosis 
(Jentink et al., 2010b). Although teratogenicity may depend on daily valproate dosage, the reported 
critical thresholds vary widely (Tomson and Battino, 2012). 
Early pregnancy exposure to carbamazepine has been reported to be linked with an approximately 
two-fold increased rate of major congenital malformation (from around 2% to approximately 
3.5–5%) in a meta-analysis (NICE, 2015a) and an Australian register analysis (Vajda et al., 2016), 
although some studies have failed to show this association (Ban et al., 2015). 
Among anomalies, spina bifida has been found to be specifically more common, but the risk is smaller 
than in the case of valproate (an approximate three-fold increased risk) (Jentink et al., 2010a). 
A meta-analysis and current controlled studies of the teratogenic potential of lamotrigine (Ban et al., 
2015; Dolk et al., 2016; NICE, 2015a; Vajda et al., 2016) suggest that it is not associated with major 
congenital abnormalities, although one population study did find a small significant increase (from 
around 3% to 5%) (Ban et al., 2015). 
 
Neonatal effects. Valproate use in the second or third trimester may be linked with increased neonatal 
problems (Kallen et al., 2013; NICE, 2015a; Pennell et al., 2012) but the evidence base is limited. 
 
Neurodevelopmental effects. Prenatal exposure to valproate is associated with lower IQ in school age 
children. The estimated difference to children of untreated women with epilepsy is approximately 8 
IQ points (Bromley et al., 2014; NICE, 2015a). In women with epilepsy, the risk of ASD is reported to 
be doubled from around 2% to 4% with in utero exposure to valproate, and childhood autism three-
fold from 1% to 3% (Christensen et al., 2013). These harmful effects of valproate may occur throughout 
fetal development. 
Current evidence does not suggest that carbamazepine is associated with poorer cognitive 
development (Bromley et al., 2014) or ASD (Bromley et al., 2014; Christensen et al., 2013; NICE, 
2015a). Although less is known about lamotrigine, current data also suggest that children are not 
affected in their neurodevelopment (Bromley et al., 2014; Christensen et al., 2013; McCorry and 
Bromley, 2015; NICE, 2015a). 
 
Breastfeeding. The serum levels of infants exposed to lamotrigine via breastmilk tend to be high, 
averaging 30–35% of maternal serum levels (Drugs and Lactation Database, 2016). One case of severe 
apnoea and other cases of CNS depression have been reported (Drugs and Lactation Database, 2016). 
Concern has also been raised regarding the theoretical risk of dermatological problems in babies 
breast fed by mothers taking lamotrigine (Drugs and Lactation Database, 2016). 
There are relatively low levels of valproate in breast milk (Drugs and Lactation Database, 2016). 
Carbamazepine levels are intermediate between valproate and lamotrigine (Drugs and Lactation 
Database, 2016) leading to a higher risk of infants experiencing side effects (sedation, poor sucking, 
withdrawal reactions and hepatic dysfunction) from ingestion. 
Conclusions/Recommendations 
• Most data relating to the reproductive safety of anti-epileptic drugs come from women with epilepsy 
and their infants. There is no reason to believe that there are differences for the medications when 
taken for bipolar disorder. 
• Valproate is associated with polycystic ovary syndrome and hence reduced fertility in women. It is 
also associated with impaired spermatogenesis. 
• Carbamazepine can reduce the effectiveness of oral and parenteral contraceptives. 
• Individual AEDs have variable and uncertain effects on pregnancy outcomes and data for AEDs 
studied as a group should not be used to counsel women regarding fetal risk. 
• Valproate is associated with a significant increased risk of a range of major congenital 
malformations, particularly neural tube defects. 
• There are some data to suggest that carbamazepine increases the risk of major congenital 
malformations but a clear estimate of risk remains undefined. 
• Lamotrigine is probably not associated with significant risks of structural teratogenicity. 
• Supplementary folate does not appear to decrease the risk of neural tube defects and other major 
congenital malformations attributed to in utero exposure to valproate or other AEDs but is advised to 
protect against the occurrence of neural tube defects associated with low folate (but see 
recommendations for Lamotrigine, below). 
• Valproate exposure in utero throughout pregnancy is associated with a decreased IQ in school age 
children and an increased risk of ASD. 
• There is no evidence that carbamazepine or lamotrigine are associated with neurodevelopmental 
problems. 
• Lamotrigine tends to pass in high concentrations into breast milk and caution is advised in using this 
in women who are breastfeeding. Carbamazepine is also found in breast milk at significant levels but 
valproate less so. 
• It is recommended that valproate is not used in female children, adolescents or women of child 
bearing potential. This, together with the use of AEDs in bipolar disorder, is described in more detail in 
‘Management of bipolar disorder’. 
 
Drugs used in the treatment of ADHD 
 
NICE recommends the use of medication as first-line treatment in adults with ADHD and moderate or 
severe impairment (NICE, 2008). Medications used to treat ADHD are increasingly being prescribed 
during pregnancy. A Danish register study found the rate increasing 5–533 per 100,000 person years 
between 2003 and 2010 (Haervig et al., 2014). It is therefore of concern that there is a paucity of data 
regarding their safety in pregnancy. 
Prior to 2014 there were extremely limited data regarding the use of methylphenidate in pregnancy. 
A systematic review reported just three papers describing a total of just 41 children exposed (Bolea 
Alamanac et al., 2014). Since then two Danish studies have reported a lack of observed congenital 
malformations following in utero exposure, including in the first trimester (Diav-Citrin et al., 2016; 
Pottegard et al., 2014). However, it is important to note that the numbers of exposed cases reported 
is low and hence these observations can only exclude malformations occurring at a high frequency. 
There have been suggestions that methylphenidate taken during pregnancy may increase the risk of 
miscarriage (Haervig et al., 2014). However, there are data which suggest that this finding may be 
confounded by indication owing to an increased risk with ADHD itself (Bro et al., 2015). Growth 
restriction and preterm delivery has been reported following abuse of methylphenidate (Debooy et 
al., 1993). 
Data have suggested that methylphenidate or atomoxetine use is associated with an increased risk of 
low Apgar score at delivery, and that this is not seen in babies born to women with ADHD not on 
treatment (Bro et al., 2015). Neonatal withdrawal symptoms are to be expected following 
methylphenidate exposure in utero close to birth, as seen with other stimulants (see ‘Stimulant 
misuse/dependence’). 
There are limited or no human data examining the effects of in-utero exposure to methylphenidate 
on neurodevelopment. Similar there are limited data on the effect of breastfeeding by mothers taking 
it. 
There are even fewer data available regarding the safety of atomoxetine use in pregnancy and during 
breastfeeding. Pharmacologically the drug is serotonin and noradrenaline reuptake inhibitor (SNRI) 
and may therefore have similar effects to those reported for similar drugs, such as venlafaxine, and 
SSRIs. It is therefore important to consider the possibility of adverse effects such as PPHN, although 
to date there have been no reports of this being linked to atomoxetine. 
Conclusions/Recommendations 
 
• There are limited data regarding the risks of in utero exposure to methylphenidate and very little 
regarding atomoxetine. 
• Current data do not suggest a link between methylphenidate exposure and congenital 
malformations. 
• Methylphenidate may be associated with an increased risk of miscarriage, but this may be a result 
of confounds related to the diagnosis of ADHD. 
• Methylphenidate exposure in utero close to delivery may be associated with a neonatal syndrome 
with low Apgar scores and stimulant withdrawal syndrome. 
• Risks associated with atomoxetine are undetermined. It is not known if it is appropriate to 
extrapolate from the data related to SNRIs and SSRIs. 
 
Drugs used in treatment of substance disorders 
 
Pharmacotherapy for substance misuse and dependence has been reviewed in other BAP guidelines 
(Lingford-Hughes et al., 2012), with more specific guidance on the integrated management of 
substance misuse in pregnant women in the NICE ‘Pregnancy and Complex Social Factors’ guideline 
(NICE, 2010a) and WHO guidelines (WHO, 2014). Other sources of information include: Confidential 
Enquiries into Maternal Deaths (Cantwell et al., 2011), Cochrane reviews on improving pregnancy 
outcomes (Whitworth and Dowswell, 2009) and reviews of psychosocial interventions and opioid 
maintenance programmes in pregnant women (Minozzi et al., 2013; Terplan et al., 2015). 
 
Smoking/nicotine dependence. A recent Cochrane review of six trials of nicotine replacement therapy 
(NRT) enrolling >1700 pregnant smokers found no differences between NRT and control groups in 
rates of miscarriage, stillbirth, premature birth, birthweight, low birthweight, admission to neonatal 
intensive care, Caesarean section, congenital abnormalities or neonatal death. They concluded that 
further research evidence on NRT efficacy and safety is needed, ideally from placebo-controlled RCTs 
(Coleman et al., 2015). NICE recommend that NRT should be considered after review of all the risks 
and benefits if interventions without NRT have failed (NICE, 2010b). 
Bupropion is licensed in the UK for smoking cessation but in many other countries it is licensed as an 
antidepressant. Most of the limited data on the drug in pregnancy come from its use to treat 
depression and do not suggest adverse pregnancy outcomes (Chun-Fai-Chan et al., 2005). There have 
been reports of cardiac defects in infants exposed in utero (Alwan et al., 2010; Louik et al., 2014), but 
the studies were small, did not fully account for all potential confounders and the nature of the cardiac 
abnormalities was inconsistent between the studies. Additional studies have also not replicated the 
findings (Huybrechts et al., 2014b; Thyagarajan et al., 2012). There are very limited data relating to 
neonatal or neurodevelopmental effects of bupropion exposure in utero. As a result of the limited 
data available, NICE has recommended that bupropion should not be used in pregnancy (NICE, 2010b), 
although there are reports of its successful use (Berard et al., 2016; Nanovskaya et al., 2016). 
A recent international prospective cohort study showed no increase in major malformation rate 
among infants of women who used varenicline during pregnancy (Richardson et al., 2016). 
However, the sample size was small, elective termination rate among this cohort was high, and in 
most cases use was discontinued prior to the major risk period for structural teratogenesis. Asthere 
are currently no other published epidemiological studies, fetal risk is undetermined and use in 
pregnancy is not advised. 
 
Alcohol misuse/dependence. The main options for alcohol detoxification in pregnancy are 
chlordiazepoxide and diazepam(Lingford-Hughes et al., 2012): see ‘Anxiolytics/Hypnotics’ on adverse 
effects of anxiolytics, although there needs to be caution extrapolating from data regarding prolonged 
use of anxiolytics for an anxiety disorder and shorter term, but often higher dose, for use during 
detoxification. Despite chlormethi azolebeing used in the past as a treatment for eclampsia there are 
no epidemiological data of its use in pregnancy from which to assess its safety. Anticonvulsants (see 
‘Antiepileptic mood stabilisers’) should only be used if the benefits outweigh the risks of fetal 
malformation or other adverse effects (Lingford-Hughes et al., 2012). 
There is an absence of evidence and clinical data on the use of relapse prevention medications 
(acamprosate, naltrexone and nalmefene) for alcohol dependence in pregnant or breastfeeding 
women (DeVido et al., 2015). There are limited data regarding disulfiram use in pregnancy, although 
the severe autonomic instability that can occur with co-ingestion of alcohol would suggest a 
theoretical risk with use in pregnant women (DeVido et al., 2015). 
 
Opioid misuse/dependence. Methadone and buprenorphine treatment in pregnancy is based on a 
considerable body of evidence on management of illicit opioid use in the general population 
(NICE, 2007) and this treatment has been found to improve maternal and fetal outcomes compared 
to those seen with untreated opioid misuse (Zedler et al., 2016). Methadone in pregnancy is 
associated with improved antenatal care, reduced maternal morbidity and improved neonatal 
outcomes (Burns et al., 2007), although a recent study found low birthweight in those on treatment 
compared to general population (Mactier et al., 2014). There are less data regarding buprenorphine 
in pregnancy, although evidence is increasing (Jones et al., 2010; Wurst et al., 2016). In a recent meta-
analysis comparing pregnancy outcomes, buprenorphine was associated with around half the risk of 
preterm birth and with greater birthweight (around 10 g) compared with methadone (Zedler et al., 
2016). No treatment differences were observed for spontaneous fetal death, fetal/congenital 
anomalies and other fetal growth measures, although the small sample sizes limit the power to detect 
such differences (Zedler et al., 2016). 
A Cochrane review found no difference between methadone and buprenorphine in rates of neonatal 
abstinence syndrome (NAS) needing treatment (Minozzi et al., 2013). The single large RCT in this 
review – the MOTHER study – did find babies of mothers treated with buprenorphine had shorter 
treatment for NAS, required less medication for NAS and had shorter stays in hospital (Jones et al., 
2010). 
 
Stimulant misuse/dependence. There is no evidence for any substitute or relapse prevention 
pharmacological treatments. Psychosocial treatments with some form of contingency management 
have the best evidence base in the general population although there is little evidence for the 
effectiveness of psychosocial interventions in pregnant drug using women (Knapp et al., 2007; Terplan 
et al., 2015). 
 Conclusions/Recommendations 
 
• The current available data on NRT suggest that it is safe to use in pregnancy. 
• Data regarding bupropion and varenicline use during pregnancy are extremely limited. 
• Safety of benzodiazepines, which may be used in alcohol detoxification is described in 
‘Anxiolytics/Hypnotics’. 
• There is a lack of human data on the safety of acamprosate, naltrexone and nalmefene. There is a 
theoretical risk of disulfiram in pregnancy if co-ingested with alcohol. 
• Methadone and buprenorphine use in women with opioid dependency is associated with improved 
fetal and maternal outcomes. 
• There are no recommended pharmacological interventions for stimulant, cannabis or NPS use in 
pregnancy. 
• Recommendations regarding the use of pharmacological interventions for substance misuse in the 
perinatal period are described in ‘Management of substance misuse’. 
 
Neuromodulatory treatments 
Given that it is impossible to fully exclude all risks associated with psychotropic medication use in 
pregnancy, it is not surprising that women with depression, for example, find psychotherapy more 
acceptable than pharmacotherapy (Goodman, 2009). However, another alternative option to 
pharmacotherapy is neuromodulatory treatment. A range of neuromodulatory treatments exist in 
psychiatry, the oldest being ECT and the use of this in pregnancy has recently been reviewed (Kim et 
al., 2015). 
  
ECT in the perinatal period. ECT is not contraindicated in pregnancy: however, given that an 
anaesthetic and muscle relaxant are required, it is not ‘medication-free’. There have been no RCTs 
assessing the safety of ECT in pregnant or breastfeeding mothers. A retrospective review of cases 
between 1941 and 2007 (Anderson and Reti, 2009) reported on 339 cases, although the quality of the 
data was not very robust. There was one fetal death secondary to status epilepticus. Overall the rate 
of fetal and maternal adverse outcomes possibly related to the ECT was around 10% but most were 
transient and not life threatening to mother or fetus. These included fetal arrhythmias, vaginal 
bleeding and uterine contractions. There was one miscarriage in the first trimester 24 h post ECT and 
one case of multiple cortical and deep white matter infarctions after multiple ECT courses but causality 
linked to ECT is hard to establish. A more recent systematic review examined 67 published case reports 
and case series including 169 women treated with 1187 sessions of ECT (Leiknes et al., 2015). Women 
had been treated for a variety of disorders including depression, bipolar disorder and schizophrenia. 
There were no maternal deaths but an overall child mortality rate of 7%, vaginal bleeding in 12%, 
premature labour in 28%, fetal cardiac arrhythmias or bradycardia in 43% and fetal malformations in 
20% of cases reported. However, given that these data are based on selectively reported cases, with 
no control population, and very mixed standards of reporting in publications from 1942 to 2013, it is 
unclear what weight to place on these findings. Note that it is reported that the risk of fetal 
bradycardia may be lower with propofol rather than methohexital (De Asis et al., 2013). 
There are limited long-term follow up data of babies born to mothers treated with ECT during 
pregnancy other than a small case series and case reports and further data are required (Kim 
et al., 2015). 
Overall, ECT is considered a possible treatment for severe depression during pregnancy but it should 
be used with caution, especially if there is a risk of vaginal bleeding or preterm birth (Kim et al., 2015; 
NICE, 2015a). Guidance exists for its use (Kim et al., 2015; Miller, 1994; O’Reardon et al., 2011; Royal 
College of Psychiatrists, 2012). 
There are virtually no data on the use of ECT in breastfeeding mothers. ECT may have a more rapid 
effect in postpartum psychosis than in non-postpartum psychosis (Reed et al., 1999). There is no 
reason to suspect that ECT is not efficacious in conditions which are known to respond to ECT at other 
times of life. Breastfeeding can be resumed as soon as the mother has recovered sufficiently from 
anaesthesia and neuromuscular blockade. It is important to consider the risks of venous thrombosis 
in the postpartum mother (Miller, 1994; Royal College of 
Psychiatrists, 2012).  
rTMS during pregnancy. Because of the lack of a need for anaesthetic or muscle relaxant during rTMS, 
this offers an option that is completely free of medication. In a survey of 1500 pregnant women, 
psychotherapy was identified as the favoured treatment option for depression during pregnancy. 
However, after being provided with information about rTMS, this was identified as an acceptable 
treatment option by only 16% (Kim et al., 2011b). There are limited data regarding the use of rTMS 
during pregnancy. An open study of 10 women reported 7 as responding, with no observed adverse 
pregnancy or fetal outcomes (Kim et al., 2011a). A subsequent open study in 30 women also reported 
no complications (Hizli et al., 2014). Additionally, a follow up study compared 18 children born to 
mothers who received rTMS during pregnancy with 26 children born to mothers with untreated 
depression during pregnancy (Eryilmaz et al., 2015), finding no difference in cognitive or motor 
development at around 30 months of age. 
 
Other neuromodulatory treatments. Like rTMS, transcranial direct current stimulation (tDCS) does not 
require any anaesthetic or muscle relaxant. As such it may be an option for women keen to avoid 
medication. However, there are no data regarding its use in the perinatal period. Deep brain 
stimulation (DBS) and vagus nerve stimulation (VNS) require surgical implantations, usually under 
general anaesthesia. However, they may be implanted prior to conception. There is a case report of 
three women with healthy pregnancies who had had DBS implanted for dystonia (Paluzzi et al., 2006), 
but there are no data in women with mental illnesses where electrode placement within the brain 
is different. There is one case report of a woman with VNS for depression who had a healthy pregnancy 
(Husain et al., 2005) and a similar one of a woman who had VNS for intractable epilepsy (Houser et 
al., 2010). 
Conclusions/Recommendation 
• The level of risks with ECT in pregnancy are unclear. Consider using ECT with caution in pregnant 
women for treatment of conditions where ECT is known to be effective (severe depression, severe 
mixed affective states, severe mania or catatonia) and in whom their physical health, or that of the 
baby, is at serious risk, or where there is insufficient time to wait for improvement with psychotropic 
medication. Follow normal good ECT practice as well as specific guidance for the use of ECT during 
pregnancy. 
• ECT may be a useful option in breastfeeding women where there may be significant risks of 
medication to the nursing infant and/or the mother’s ability to care for her child. 
• There are very limited data on rTMS during pregnancy or breastfeeding, but this may offer a 
medication-free treatment option for some women. 
• There are no data for the use of tDCS in the perinatal period and very limited data regarding DBS and 
VNS. 
 
Recommendations for the pharmacological management of specific disorders 
 
This section should be read in conjunction with the section ‘Using medication in the perinatal period’ 
that describes the general principles of prescribing in the perinatal period, particularly ‘Recommended 
principles of prescribing to women in the perinatal period’. The advice in ‘Using medication in the 
perinatal period’ is relevant to all psychiatric disorders. A key point worth repeating is that it is always 
worth considering non-pharmacological management options, such as psychological interventions, as 
possible alternatives to medication. This point will not be reiterated in each of the sections below 
which will focus on pharmacotherapy. 
 
Management of depression 
Pre-conception 
• Decisions on whether to continue or commence antidepressant treatment need to be individualised. 
See section ‘Recommended principles of prescribing to women in the perinatal period’ regarding 
factors influencing decisions and section on ‘Antidepressants’ for specific risks of antidepressants in 
the perinatal period. 
• None of the currently available antidepressants is absolutely contraindicated in pregnancy. Most 
guidelines recommend SSRIs as first-line pharmacological treatments for depression (Cleare et al., 
2015; NICE, 2009). Additionally, the largest evidence base around reproductive safety is for the SSRIs. 
As a result, this makes them first choice treatments preconception and in pregnancy for antidepressant 
naïve women. 
• For non-antidepressant naïve women decisions about which antidepressant to use should follow the 
generic guidance around choice of drug laid out in the section ‘Recommended principles of prescribing 
to women in the perinatal period’. 
• Care should be taken in women with treatment resistant depression who are being prescribed 
medication to augment their antidepressants. In particular, it should be noted that there is no evidence 
to support the use of anticonvulsant mood stabilisers as adjunctive agents for unipolar depression 
(Cleare et al., 2015; Haddad et al., 2015). Given the particularly high risks associated with valproate, 
use in women of childbearing potential with unipolar depression should be avoided altogether. 
 
Antenatal 
• Note all of the recommendations for the pre-conception period above. 
• In general, antidepressants should not be discontinued suddenly on discovering a pregnancy due to 
risks of discontinuation syndrome and relapse. 
• In late pregnancy, there is a risk/benefit decision to be considered around the risk of PPHN that is 
associated with antidepressants. 
• There is a lack of evidence and consensus on whether reduction/discontinuation or maintenance of 
antidepressant close to delivery will alter the risk of poor neonatal adaptation. Discontinuing 
antidepressants before delivery may place the mother at an increased risk of relapse and importantly 
postnatal depression. 
• There are very limited data on rTMS during pregnancy, but this may offer a medication-free 
treatment option for some women.  
 
Postnatal 
• There is substantial evidence that women who are depressed in pregnancy are at an increased risk 
of depression postnatally. For these women, if antidepressant treatment is required in pregnancy, it is 
likely to be of benefit for it to continue in the postpartum period. 
• Women who are well in pregnancy, but who have had a previous episode of depression postnatally, 
may also be at increased risk of subsequent postnatal recurrence. However, there is limited evidence 
for pharmacological interventions that can reduce this risk and decisions should be made on an 
individual basis. 
• Pharmacological treatment of depression postnatally does not differ substantially from depression 
at other times. The most distinctive consideration is in relation to breastfeeding (see Recommended 
principles of prescribing to women in the perinatal period: Postnatally and during breast feeding). 
|| As in choosing medication in pregnancy, there is a different risk/benefit analysis to be made 
depending on whether a woman is initiating antidepressant treatment or is already taking medication. 
For initiation, sertraline is associated with low transfer into breastfed babies and associated adverse 
effects. However, the risks of other antidepressants may be outweighed by their clinical advantages 
for continuation treatment. 
• It makes good clinical sense that choice of antidepressant in pregnancy takes into account 
breastfeeding intentions, avoiding the need to consider alteration of treatment in the early postpartum 
period, at a time of heightened risk. 
 
Management of anxiety disorders and insomnia 
• The impact of untreated anxiety and insomnia during pregnancy is significant (see section ‘Risks 
related to anxiety, stress and insomnia’). There is uncertainty as to whether treatment decreases any 
long-term risks to the child but this should not be a reason not to treat if maternal 
symptoms are affecting maternal wellbeing. 
• Decisions on whether to continue or commence treatment need to be individualised. See 
‘Recommended principles of prescribing to women in the perinatal period’ regarding factors 
influencing decisions including between medication and non-pharmacological options. 
|| If the disorder is causing severe distress and/ or impairment then medication may be required 
(Baldwin et al., 2014). 
|| In choosing a medication consider the woman’s previous treatment history and, especially if 
treatment naïve, recommendations regarding treatment in nonpregnant patients (Baldwin et al., 
2014). 
|| SSRIs are first-line pharmacological agents for generalised anxiety disorder, panic disorder, social 
anxiety disorder, PTSD and OCD in non-pregnant patients (Baldwin et al., 2014). Given the relatively 
large database regarding their safety in the perinatal period, they are also the first-line treatments for 
these anxiety disorders pre-conception and antenatally (see sections ‘Antidepressants’ and 
‘Management of depression’). Be aware of the limited data regarding other anxiolytics in pregnancy 
(see ‘Anxiolytics/Hypnotics’). 
|| It is important to note that insomnia postnatally (inability to sleep even when not being disturbed 
by the baby) may herald or even precipitate severe illness such as postpartum psychosis (see below). 
|| Review the need for treatment regularly and use for the shortest period necessary. 
 
Management of bipolar disorder  
General management issues across all childbearing stages 
• The aim of management is to achieve optimal mood stability at a critical time in the woman’s life. 
• Because of the complexities and risks of bipolar disorder in the perinatal period, treatment decisions 
need to be based on an up-to date and in depth psychiatric assessment of the woman at the first 
psychiatric contact in the preconception or perinatal period (see section ‘Recommended principles of 
prescribing to women in the perinatal period’). 
• Raise the woman’s awareness that stressors, irregular activity patterns and sleep disturbance can 
trigger bipolar relapse (Goodwin et al., 2016). Minimising them is particularly challenging at the end 
of pregnancy and in the postnatal period. The mental health team should 
ensure that the woman has appropriate support and strategies in place to reduce their impact. 
• Given the high rate of substance misuse (including alcohol and tobacco) seen in bipolar disorder, it is 
important to discuss measures to reduce this. 
• Self-monitoring by, for example, using mood diaries is an important element of the management of 
bipolar disorder in any patient at any time (Goodwin et al., 2016). 
• Since there is no or insufficient trial data for pregnant or postnatal patients with bipolar disorder, the 
efficacy of different medication options needs to be extrapolated from other patient groups, and from 
the experience of the individual patient. 
 
Pre-conception and antenatally 
 
• Because antipsychotics have a better risk/benefit ratio than valproate and carbamazepine, and a 
larger reproductive evidence base and possibly better reproductive safety profile than lamotrigine and 
lithium, they generally form the mainstay of the treatment of women in the perinatal period (see 
sections ‘Antipsychotics’, ‘Lithium’ and ‘Antiepileptic mood stabilisers’). SGAs generally have a larger 
evidence base than FGAs for use in bipolar disorder (Goodwin et al., 2016). 
|| If a woman planning a pregnancy is taking an antipsychotic drug with prolactin elevating potential, 
she should be asked about her menstrual cycle. Any patient reporting oligo- or amenorrhoea should 
have a prolactin level measured. If she has hyperprolactinaemia that is thought to be caused by 
antipsychotic medication, consider switching medication to a prolactin- sparing agent, such as 
quetiapine or olanzapine (Haddad and Wieck, 2004). 
|| During pregnancy, prolactin raising antipsychotics can be prescribed. 
• In general, valproate should not be prescribed to any female child or adolescent, or woman who is of 
childbearing potential, pregnant or planning a pregnancy (NICE, 2015a). 
|| Note that the Medicines and Health Products Regulatory Authority in the UK (2015) considers an 
exception to this advice for a group of women with childbearing potential who have not responded to 
any other medication (https://www.gov.uk/drugsafety- update/medicines-related-to-valproate-risk 
of- abnormal-pregnancy-outcomes). These women can be prescribed valproate if they have mental 
capacity, if pregnancy is excluded and they are well enough to make consistent use of highly reliable 
contraception. A toolkit for clinicians and patients is available 
(https://www.gov.uk/government/publications/toolkit-on-the-risks-of-valproate-medicines-
infemale- patients). 
|| If a woman planning a pregnancy is already taking valproate, it should (unless exceptional 
circumstances pertain) be withdrawn gradually over at least 4 weeks (Goodwin et al., 2016) while the 
woman uses effective contraception. 
|| Should a woman become pregnant while taking valproate it should usually be withdrawn. Consider 
replacing it with an antipsychotic drug. 
• In general, do not initiate carbamazepine in preconception or pregnant women because of its 
teratogenic potential and uncertain efficacy in bipolar disorder (Goodwin et al., 2016). 
|| If a woman is already taking carbamazepine, discuss with the woman the possibility of stopping the 
agent. 
• If lamotrigine is used in pregnancy be aware that: 
|| Serum concentrations of total and free lamotrigine decline markedly due to pregnancy-induced 
alterations in the activity of glucuronosyl transferases and renal function. The extent is highly variable 
(Tomson et al., 2013). To aid the management of depressive relapses in the perinatal period, serum 
levels should be monitored from preconception, if possible, until the first month postpartum when 
levels should return to pre-pregnancy values. 
|| Preliminary evidence suggests that folic acid supplements may reduce the effectiveness of 
lamotrigine (Geddes et al., 2016). 
• There is little evidence that the use of folic acid mitigates AED induced harm to the fetus. NICE 
guidelines for epilepsy recommend high dose folic acid before any possibility of pregnancy for women 
on AEDs including lamotrigine (NICE, 2012). However, there is uncertainty regarding the effectiveness 
of this (see sections ‘Recommended principles of prescribing to women in the perinatal period’ and 
‘Teratogenicity’). There is also the concern regarding the effect of folate on the efficacy of lamotrigine 
(see above). Nevertheless, it is recommended to prescribe a high dose (5 mg/day) in the 3 months 
before and after conception, certainly for patients on valproate and carbamazepine and possibly those 
on lamotrigine. 
• If lithium is prescribed during pregnancy: 
|| Inform the obstetrician of any first trimester exposure and request particular attention towards fetal 
screening for cardiovascular anomalies. 
|| If the plan is to discontinue lithium it should be tapered gradually over 4 weeks. Consider restarting 
in the second or third trimester. 
|| Lithium levels tend to decrease in pregnancy but can also sometimes increase again, particularly in 
late pregnancy. Measure plasma levels once a month until 36 weeks of pregnancy and then weekly 
until delivery. As ever, it is important that women are instructed to avoid dehydration. 
|| Women taking lithium should deliver in hospital and be monitored by the obstetric team. 
|| To prevent maternal and neonatal intoxication, lithium should be suspended for 24–48 h before a 
planned Caesarean section or induction, and at the onset of labour (Newport et al., 2005) and the 
lithium level should be measured 12 h after the last dose. If levels are not above the therapeutic range, 
restart lithium on day 1 postnatal and check the level again after 1 week. 
• Stopping medication other than lithium before delivery is not known to have any benefits for the 
neonate but may place the mother at a greatly increased risk of bipolar relapse.  
 
Postnatal 
 
• Postnatal bipolar recurrences and new onset bipolar and other affective postpartum psychoses tend 
to commence suddenly in the first few days after delivery, progress rapidly and be severe. They pose 
serious risks to the safety of mother and child. These illnesses need to be identified early, regarded as 
psychiatric emergencies and managed effectively with medication. 
|| In women who have pre-existing bipolar disorder and who are unmedicated in pregnancy, re-
starting previously effective medication, or an antipsychotic such as quetiapine or olanzapine, on the 
first day after childbirth may prevent some, but not all, early recurrences. 
|| The duration of treatment that should be used for prophylaxis postnatally is uncertain. In the 
absence of such evidence it is recommended to follow recommendations around prophylaxis in the 
non-perinatal situation (Goodwin et al., 2016; NICE, 2014). 
|| In severe postpartum affective states that are associated with high risks or poor response to 
medication, ECT should be considered (see ‘ECT in the perinatal period’). 
|| Any antipsychotic medication that is effective in bipolar disorder can be considered during 
breastfeeding with the possible exception of lurasidone (due to a limited evidence base) and clozapine 
(due to risks of agranulocytosis – see section ‘Antipsychotics’). 
|| Lithium, valproate and carbamazepine should not be prescribed to women with affective disorders 
who breastfeed. 
|| Lamotrigine can be prescribed during breastfeeding but infants should be carefully monitored for 
potential side-effects. If there is any concern, consider measuring infant serum levels. Discontinue 
lamotrigine if the baby develops a skin rash until the cause has been established (Drugs and Lactation 
Database, 2016: https://www.nlm.nih.gov/pubs/factsheets/lactmedfs. html). 
 
Management of schizophrenia and psychosis 
 
Management across all childbearing stages 
 
• Take into account the general principles laid out in section ‘Recommended principles of prescribing 
to women in the perinatal period’. 
 
Pre-conception 
• Discuss contraception and pregnancy plans with all women of reproductive age who have 
schizophrenia or other psychosis. Do not assume impaired fertility. Note that if switching to a prolactin-
sparing drug discuss fertility changes. 
• If a woman who is on a prolactin-raising drug is struggling to get pregnant consider switching to a 
prolactin-sparing antipsychotic. She may still have difficulties conceiving due to other factors, such as 
stress and obesity. 
• Discuss the risk of relapse in pregnancy (similar to risk of relapse outside the perinatal period) and in 
the postpartum period (higher than the risk of relapse outside the perinatal period, but not as high or 
as sudden as in bipolar disorder). 
• If the woman is taking an antipsychotic that is effective for her, continue with this medication unless 
the evidence on risks outweigh the benefits. 
|| Consider that the risk of switching to an alternative antipsychotic is that beneficial effects on the 
mother’s illness may be lost with the fetus still exposed to some risk. 
|| If, after taking these considerations into account, there is a decision to switch antipsychotic, choose 
the drug with the lowest risk profile for the woman, fetus and baby, taking into account a woman’s 
previous response to medication. 
|| If she is established on clozapine, continue with this medication if the benefits are likely to outweigh 
the risks. Screen for diabetes and monitor fetal growth. Advise the woman that breastfeeding while on 
clozapine is not recommended (risk of infant agranulocytosis). 
|| If she is established on depot, continue with this medication if the benefits outweigh the risks, and 
in particular if there is a history of poor compliance with oral medication and a high risk of relapse. 
Ensure all health professionals are aware of drug pharmacokinetics and the need for prolonged 
monitoring for neonatal symptoms and any other suspected adverse effects. 
 
Antenatal 
• If a woman decides to stop an antipsychotic, ensure she is offered optimal psychosocial interventions 
and monitored closely. If there is a deterioration in her mental state, consider the need for admission 
or the use of the compulsory detention. 
• Discuss breastfeeding plans, bearing in mind the likely need to continue antipsychotics in the high-
risk postnatal period. 
 
Postnatal period 
• The risk of relapse is higher in the postnatal period than during pregnancy, so maintain effective 
treatment. 
• Avoid switching or stopping medication in the postnatal period unless there is good reason for doing 
so (e.g. serious adverse maternal effects such as sedation). 
• Encourage women who are taking an antipsychotic to breastfeed, unless they are taking clozapine. 
|| However, monitor infants for sedation, feeding problems, motor abnormalities and 
neurodevelopment. 
 
Management of eating disorders 
 
Pre-conception 
 
• A healthy BMI should be achieved prior to assisted reproduction (NICE, 2013). 
• Specialist ED treatment should be provided for women who have a history of an ED and who are 
experiencing difficulties conceiving. Ideally a reduction in symptoms should be achieved prior to 
conception. 
 
• Unplanned pregnancies are common among women with AN, as women may assume that they are 
unable to conceive due to menstrual irregularities (Bulik et al., 2010; Easter et al., 2011; Micali et al., 
2014). Routine pre-conception advice and psycho-education should therefore be 
provided. 
  
Antenatal 
 
• Women with ED often do not disclose their ED to healthcare professionals in the antenatal 
healthcare setting (Taborelli et al., 2015; Tierney et al., 2011). It is therefore recommended that 
questions relating to eating and weight control behaviours are routinely asked in early pregnancy, 
especially in high-risk women (see e.g. (NICE, 2004). 
• Women who describe ED symptoms or have a threshold or sub-threshold ED in the perinatal period 
should be offered a multi-disciplinary assessment and specialist treatment where appropriate. 
• Pharmacological treatment for ED has not been investigated in pregnant women. 
|| Given the lack of pharmacological treatments for AN, drug treatment might only be beneficial in 
treating comorbid physical or psychological conditions. 
|| Although fluoxetine is a treatment option for BN, CBT is the first-line treatment and might be more 
appropriate during pregnancy. 
|| Similarly, although pharmacological options are available for BED, given the stronger evidence of 
efficacy for psychological treatments, these are recommended in pregnancy. 
• Most women with current or past ED will be unsure about adequate nutritional requirements and 
will be intensely preoccupied with the adequate amount of weight gain needed and specific macro 
and micronutrient nutritional requirements. They might benefit from dietetic support and 
management. 
|| The US Institute of Medicine recommends specific weight gain ranges depending on women’s BMI 
(Rasmussen et al., 2009). 
|| Women who fail to gain adequate weight gain and continue to be underweight (BMI < 18.5) 
during pregnancy are at risk for adverse birth outcomes and might require intensive multi-
disciplinary treatment, nutritional management and in severe cases hospitalisation and statutory 
assessment. 
 
Postnatal 
• Given the high likelihood of ED relapse or recurrence postpartum (Bulik et al., 2007) and higher 
prevalence of postnatal depression (Easter et al., 2015; Micali et al., 2011b), women with active ED 
or history of ED should receive psychiatric monitoring postnatally. 
• Studies show that mothers with ED have difficulties in feeding their infants (Micali et al., 2011a) 
and might find motherhood generally difficult. They are therefore likely to benefit from specific 
support during the first 6-months of life. 
 
Management of ADHD 
• There are limited data regarding the safety of medications used to manage ADHD in the perinatal 
period (see ‘Drugs used in the treatment of ADHD’). There are more data with regards to 
methylphenidate exposure than for atomoxetine. 
• The decision as to whether medication should be continued during pregnancy and breastfeeding, 
and the choice of which to use should follow the principles laid out in the section ‘Using medication in 
the perinatal period’. 
 
Management of substance misuse 
• The WHO guidelines on the identification and management of substance use in pregnancy (WHO, 
2014) are recommended. 
• Women should be asked about the use of illicit drugs and supported to stop and remain abstinent. 
• It is important to encourage early and accessible access to antenatal care, and provide integrated 
care with primary care, addiction services, obstetric and perinatal services, with emphasis on child 
safeguarding, good communication and planning for support for mother and baby 
(Knight et al., 2015). Harm reduction information should be provided. 
 
Smoking/nicotine dependence 
 
• All pregnant women who smoke should be referred to smoking cessation services and psychosocial 
interventions known to be effective should be offered. 
• NRT is preferable to smoking and associated with better pregnancy outcomes. 
• NRT should be offered after risk–benefit analysis if other non-pharmacological interventions have 
failed. 
• Bupropion and varenicline should not generally be prescribed during pregnancy or breastfeeding. 
Alcohol misuse/dependence 
• NICE provides guidance on the detection and treatment of alcohol misuse in pregnancy (NICE, 
2010a, 2011). 
• The UK Chief Medical Officers’ advice (UK Chief Medical Officer, 2016) is unambiguous: ‘if you are 
pregnant or planning a pregnancy, the safest approach is not to drink alcohol at all, to keep risks to 
your baby to a minimum’. 
• Pregnant women should be screened for alcohol use with advice on cessation or at the least using 
minimal amounts. In general, advice on fetal alcohol syndrome should be readily available. 
• Psychological and educational interventions may result in increased abstinence from alcohol, and a 
reduction in alcohol consumption among pregnant women (Stade et al., 2009), but there have been 
no trials in women with both mental disorders and alcohol abuse. 
• Chlordiazepoxide or diazepam are the treatments of choice for alcohol detoxification in pregnant 
women requiring a medicated withdrawal of alcohol. They should ideally be used in an inpatient 
setting. 
• Due to a lack of human data, acamprosate, naltrexone, nalmefene and disulfiram are not 
recommended for use in pregnancy or lactating women (see section ‘Alcohol misuse/ dependence’). 
Opioid misuse/dependence  
• Given evidence of the benefit of their use in pregnancy, methadone and buprenorphine treatment 
should be offered to those dependent on opioids as part of an integrated and comprehensive treatment 
programme including addiction services, primary care and obstetric staff. 
|| The choice of methadone or buprenorphine should be based on individual need and the woman’s 
preference with informed consent after a comprehensive assessment. 
|| The aim of treatment should be to eliminate illicit drug use for those commencing treatment or 
prevent relapse to illicit drug use in those already on substitution therapy. 
• Pregnant women already receiving buprenorphine should not be advised to transfer to methadone 
unless they are not responding well to buprenorphine treatment (WHO, 2014). 
• Buprenorphine–naloxone combination medication should not be used. 
• Pregnant women already receiving methadone substitution treatment should be advised not to 
transfer to buprenorphine due to the risk of opioid withdrawal (World Health Organisation, 2014). 
• The dose of methadone to be used in pregnancy is a matter of debate: enough to limit illicit drug use, 
or to use lowest dose to avoid a NAS (Gray et al., 2010). 
• There is little evidence for detoxification. 
|| Slow reduction with monitoring can be undertaken during second and third trimester, provided 
stability is maintained in all aspects of care. 
|| Pregnant opioid dependent women should be encouraged to access opioid maintenance treatment 
rather than attempt detoxification, on the basis that relapse rates are high and the maternal and fetal 
risks are greater from failed detoxification and from relapse to illicit drug use than from opioid 
maintenance treatment (WHO, 2014). 
• Management of pain in labour should be discussed with the woman and obstetric team. 
 
Stimulant misuse/dependence 
 
• Pregnant women are advised to stop all stimulants, including all NPS. 
• Psychosocial interventions should be offered. 
• There are no substitute pharmacological treatments that are recommended. 
 
Benzodiazepine misuse/dependence 
• Pregnant women misusing benzodiazepines should have a comprehensive assessment of their drug 
use. 
• Aim for gradual dose reduction with a long-acting benzodiazepine, e.g. diazepam (WHO, 2014). 
|| The lowest effective dose to prevent maternal withdrawal symptoms should be used. 
|| A slow reduction is recommended with close liaison with the obstetric team. 
|| Psychosocial interventions should be provided alongside pharmacotherapy and inpatient admission 
considered. 
 
Management of personality disorders 
• There are limited or no data regarding the pharmacological management of personality disorders in 
the perinatal period. 
• Follow the generic prescribing recommendations made in ‘Using medication in the perinatal period’. 
Given the paucity of data of efficacy of psychotropics in personality disorders, it is particularly 
important to consider carefully the risk/benefit balance of the medication. 
• Often pharmacotherapy in personality disorders is used on a symptomatic basis. In this regard, follow 
the recommendations in the relevant subsection of the section ‘Recommendations for the 
pharmacological management of Specific disorders’. 
 
Management of acute behavioural disturbance 
• Acute behavioural disturbance may occur in pregnant and postnatal women in the context of severe 
mental illness, whether the condition occurs de novo or is a result of relapse of a previous or known 
condition. Timely and appropriate management is important because of the particular risks that the 
disturbance may present in the perinatal period, i.e. physical risks to the pregnant woman, risks to the 
delivered woman who may be physically compromised in relation to recent childbirth (e.g. post 
Caesarean section, sepsis etc.), physical risks associated with the environment (e.g. in theatre, labour 
ward, birthing pool etc.) and not least the risk a mother’s disturbed behaviour may pose to a vulnerable 
infant. 
• Good practice in relation to prevention of behavioural disturbance and de-escalation techniques must 
be followed. 
• Be particularly aware of the increased risks of behavioural disturbance in the perinatal period due 
to: 
|| The risk of sudden and severe relapse postnatally in women with bipolar affective disorder 
|| The risk of a woman developing a psychotic episode for the first time post-childbirth 
|| The risk of relapse associated with non-adherence to medication where a woman does not take her 
medication due to fears that the fetus/infant will be adversely affected. 
• Clinicians in both psychiatric and obstetric units should be familiar with how to manage acute 
behavioural disturbance in the perinatal period. 
• Women who are at a known risk of relapse and attendant behavioural disturbance should have a 
clear plan in their records as to how this will be managed (including what medication might be used) 
and this plan should be shared with all professionals and services who work with the woman. 
• The aim of rapid tranquillisation is to: 
|| Avoid prolonged physical intervention. 
|| Prevent/reduce harm to woman physically and psychologically. 
|| Prevent harm to others including the fetus/infant. 
• A pregnant woman requiring rapid tranquillisation should be treated according to the NICE clinical 
guidelines for the short-term management of violence and aggression (NICE, 2015c) as well as relevant 
disorder specific guidance. 
• The mother should NEVER be secluded or left alone after rapid tranquillisation. 
• Restraint procedures should be adapted to avoid possible harm to the fetus and mother. This will 
mean that the woman must not be laid supine (risk of obstruction to major blood vessels) or prone (risk 
to fetus). Any unit that has a pregnant woman admitted should have large beanbags available so that 
the woman can be lowered into the beanbag and therefore retain a semi-seated position 
where she is supported. 
• When choosing an agent for rapid tranquillisation in a pregnant woman, an antipsychotic or a 
benzodiazepine with a short half-life should be considered. 
• If an antipsychotic is used, it should be at the minimum effective dose because of the risk of neonatal 
extra pyramidal symptoms. 
• If a benzodiazepine is used, the risks of floppy baby syndrome should be taken into account. 
• Decisions on choice of medication should be made on an individual basis taking into account both 
the risks to the mother and to the fetus. 
• Intramuscular injections for rapid tranquilisation may be administered into the gluteal muscle or the 
lateral thigh. 
• After rapid tranquillisation the woman must be reviewed by a midwife to look for signs: 
|| That the fetus may have been harmed by the procedure. 
|| That the mother is in labour, as rapid deterioration in mental state towards the end of pregnancy 
may indicate that the mother is going into labour. 
• During labour, if the woman becomes acutely disturbed, her care should be managed in close 
collaboration with midwifery, a paediatrician, an anaesthetist and psychiatry. All interventions should 
be documented and communicated verbally in handover to all professionals. 
• If the woman is acutely disturbed in the postnatal period it is important that another adult has 
responsibility for caring for the infant. 
|| Clinicians must hold in mind that if the mother’s symptomatology incorporates the infant and the 
infant is removed from her or kept at a distance from her, then she may become even more agitated 
and distressed. 
|| Clinicians on psychiatric Mother and Baby Units and acute wards that admit pregnant women 
should develop competence through role play, discussion and multi-disciplinary learning in managing 
the acutely disturbed pregnant and postnatal woman. Care plans must recognise that a woman may 
become acutely disturbed. 
• The teams providing care must ensure that the woman is kept hydrated, and that observations of 
temperature, pulse, BP, respiratory rate and oximetry are carried out regularly and documented. 
• Over-sedation has particular risks for the pregnant and postnatal woman particularly if she resumes 
care of her infant. Effects on the fetus of drug exposure through the placenta or to the infant in 
breastmilk must be considered and appropriate precautions taken. 
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